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ABSTRACT
Machine Learning and Solvation Theory for Computer-Aided Drug Discovery
by Lieyang Chen
Adviser: Dr. Tom Kurtzman

Drug discovery is a notoriously expensive and time-consuming process; hence, developing computational
methods to facilitate the discovery process and lower the associated costs is a long-sought goal of
computational chemists. Protein-ligand binding, which provides the physical and chemical basis for the
mechanism of action of most drugs, occurs in an aqueous environment, and binding affinity is determined
not only by atomic interactions between the protein and ligand but also by changes in their interactions with
surrounding water molecules that occur upon binding. Thus, a quantitative understanding of the roles water
molecules play in the protein-ligand binding process is an essential foundation for developing computational
methods and tools to aid the drug discovery process.

Grid inhomogeneous solvation theory (GIST) is a tool that measures the thermodynamic and structural
properties of water molecules on protein surfaces. Since its implementation, GIST has been used to study
water behavior upon protein-ligand binding and to account for solvent effects in scoring functions used in
virtual screening. This thesis is comprised of two research projects that extend the applications and
functionality of GIST. In the first project, we investigated whether the water properties measured by GIST
could improve the performance of machine learning models, specifically, convolutional neural networks
(CNN) applied to virtual screening (GIST-CNN project). In the second project, we implemented the particle
mesh Ewald (PME) algorithm for energy calculation in GIST, enabling GIST to become a more accurate
and more efficient tool for end-state free energy calculation (PME-GIST project).

The GIST-CNN project arose in response to reports indicating that convolutional neural network (CNN)
models were able to outperform classical scoring functions in virtual screening. We noticed that all the
reported machine learning models had been trained only by protein-ligand structures, while water molecules
were completely neglected. Given that water molecules play essential roles in protein-ligand binding, we
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hypothesized that we could further improve the performance of CNN models in terms of enrichment
efficiency by adding water features, measured by GIST, to the data used to train the model. Contrary to our
hypothesis, we found that adding water features could not further improve the performance of a CNN model
trained by protein-ligand structures, which was already very high. However, further investigation revealed
that the high performance and reported enrichment efficiency of a CNN model trained by protein-ligand
information was solely attributable to biases in the Database of Useful Decoys-Enhanced (DUD-E), which
was used to train and test the model. In this project, we also established a suite of methods to investigate
what a model learns from the input during training and argued that machine learning models should be
thoroughly validated before being applied in real drug discovery projects.

The motivations for the PME-GIST project were twofold. First, although GIST provides the statistical
thermodynamic framework for thermodynamic end-state free energy calculation, inconsistencies in energy
calculations between the previous GIST implementation (GIST-2016) and modern molecular dynamics
engines prevent precise comparison of the GIST end-state method to other reference free energy
calculation methods such as thermodynamic integration (TI). Second, the O(N2) nonbonded energy
calculation is the most expensive step in the entire GIST calculation process. By implementation of the
PME algorithm into GIST, we aimed to achieve GIST energy calculations consistent with those of modern
molecular dynamic engines and to accelerate the energy calculation to O(NlogN), which is highly desirable
when applying GIST to the measurement of water properties across an entire protein surface. In addition
to implementing PME, we derived a simple empirical estimator for high order entropies, which are truncated
in GIST. After incorporating PME-based energy calculation and the high order entropy estimator, we used
PME-GIST to calculate end-state solvation free energy for a wide range of small molecules and achieved
results highly consistent with TI ( R 2 = 0.99, mean unsigned difference = 0.44 kcal/mol). The PME-GIST
code we developed in this project was integrated into the open-source molecular dynamics analysis
software CPPTRAJ for easy access by others in the drug discovery community.

In summary, in this thesis, we explored the potential of adding solvation thermodynamics to machine
learning-based virtual screening and found that the high performance reported for machine learning models
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in this application reflected biases in the dataset used construct and test them rather than successfully
generalization of the physical principles that govern molecular interactions. We also addressed the
inconsistent energy calculation between GIST and modern molecular simulation engines by developing
PME-GIST. We hope the research work presented in this thesis will further expand and accelerate the
application of GIST to drug discovery.
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PREFACE
This thesis has three chapters. In Chapter One, I introduce the workflow that governs the modern drug
discovery process. With a brief overview of the history of drug discovery for context, we will see that the
modern drug discovery process driven by the application of advanced biological and chemical techniques,
was mainly established after the 20th century. The concept of using computers to aid in the drug discovery
process was not introduced until the 1980s. Thanks to the ingenuity of and effort invested by computational
chemists over the last four decades, computational tools are now powering every step of the drug discovery
process. Chapter One will also provide a brief overview of prevalent computational methods that have been
applied to modern drug discovery.

In Chapter Two, I first introduce the two major approaches for virtual screening: Ligand-based Virtual
Screening (LBVS) and Structure-based Virtual Screening (SBVS). For LBVS, I mainly discuss how
fingerprint-based similarity searching is applied to find actives that are similar to known ligands. For SBVS,
I mainly discuss how molecular docking is applied to this task and focus on types of scoring function that
are implemented in docking programs. After this, I also introduce the concept of machine learning and
prevalent machine learning models. Having provided background on classical approaches for virtual
screening and machine learning, I then present the GIST-CNN study, wherein we applied convolutional
neutral networks for virtual screening using DUD-E and concluded that inherent biases in training datasets
like DUD-E should be addressed before machine learning approaches can be reliably applied to real drug
discovery projects.

In Chapter Three, I first introduce GIST and TI. I also discuss the limitations of the energy calculation in the
previous GIST implementation (GIST-2016). I then present the results of the PME-GIST study, wherein we
incorporated the PME algorithm into GIST to address these limitations and compared solvation free energy
calculations from PME-GIST and TI.

xvii

Chapter 1: Modern Drug Discovery
1.1 Overview of the Drug Discovery Process
Human use of substances from plants to prevent and cure diseases can be dated back to thousands of
years ago. For example, Li Shizhen recorded the 1892 materia medica of Chinese medicine known at the
time—from plants, animals, and minerals—in a Chinese herbology volume called Compendium of Materia
Medica (Chinese name: 本草纲目) published in 1578. Before the 19th century and the development of
chemistry as a science, medicinal professionals used simple isolation methods such as milling to extract
active substances from organisms known to have medicinal properties.

In the 19th century, chemistry started to develop, and chemists gained the ability to isolate or synthesize
chemical substances with high purity. For example, morphine was first purified by German pharmacist
Friddrich Sertürner from the plant Papaver somniferum between 1803 and 1805 for use as a pain
medication. Choral hydrate, the first synthetic sedative, was synthesized by German chemist Justus von
Liebig in 1832. During this early history, drug discovery focused on the synthesis of new chemicals or
isolation of active compounds from natural products such as microorganisms, plants and animals, but there
was no way to predict which compounds would be therapeutically useful to direct these efforts, and
therapeutic effects of many new compounds were discovered by accident. A famous example is the
discovery of penicillin. Antibacterial properties of Penicillium molds and other fungi had been noted
anecdotally by physicians and scientists starting from the late 1870s. In 1928, the Scottish physician
Alexander Fleming took these observations further, designing experiments and identifying penicillin as the
active antibacterial substance. Today, penicillin is still considered to be one of the most important drugs of
all time and is estimated to have saved millions of lives during World War II.

Attributable to the theoretical and technological revolutions in physics, biology, and chemistry since the 20th
century, the drug discovery process has pivoted from fortuitous discovery of active compounds to their
rational design. One critical milestone in this transition was the discovery of the double helix structure of
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DNA in 19531; this laid the groundwork for the development of gene sequencing and cloning technology in
the 1970s and 80s, which allowed biologists to express human proteins of interest in bacteria and test the
effectiveness of compounds against these proteins in vitro. Another milestone was the solving of the first
protein structure, myoglobin, by English crystallographer John Kendrew in the 1950s using X-ray diffraction2,
a technique that has since been widely used for guiding drug discovery. Ethical and regulatory frameworks
governing drug discovery and approval were also shaped in the 20th century. In the 1930s, the Federal
Food, Drug, and Cosmetic Act was signed by United States president Franklin Delano Roosevelt, and the
Food and Drug Administration (FDA) was charged with overseeing verification of the safety and efficacy of
new drugs for public use in the United States. Later on, the U.S. National Research Act of 1974 and Belmont
Report of 1979 were instrumental in establishing the ethics of conducting medical research involving human
subjects.

After decades of evolution, the modern drug discovery process comprises target identification and validation,
hit generation, lead optimization, preclinical development, and clinical trials. In the following sections, each
of these stages of the modern drug discovery process will be introduced with a focus on how computational
methods are applied at each stage, especially after the drug target is identified.

1.1.1 Target Identification and Validation
Identifying the molecular pathogenesis of a disease and evaluating the therapeutic potential of perturbing
the pathogenic process is the first step in the drug discovery process. Given that almost all biological
processes, such as signal transduction and enzyme-catalyzed reactions, are regulated and mediated by
proteins, a significant percentage of drug targets identified so far are proteins. According to a
comprehensive study by Rita Santos et al. in 20173, the leading human drug targets are G protein-coupled
receptors (GPCRs) (12%), ion channels (19%), and kinases (10%), all of which are proteins. In this thesis,
discussion of the theories and techniques in drug discovery is focused on human protein targets unless
otherwise specified.
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Through decades of effort in basic biochemical research, the roles of DNA, RNA, and proteins and how
they work together to ensure the normal functioning of cells have become understood in greater and greater
detail. Facilitated by the completion of the human genome project in 2003 and the rapidly declining cost of
genome sequencing, large-scale genomic studies such as genome-wide association studies (GWAS) have
been applied to uncover associations between genetic variants and the occurrences of a wide range of
dieases4. Efficient and precise genomic editing tools based on systems such as RNA interference (RNAi)
and clustered regularly interspaced short palindromic repeats (CRISPR)5 have also been developed and
applied to study the roles of specific genes within the cell. Together, these advances have contributed to
the identification of molecular pathogenesis of a variety of diseases, thereby providing the biological basis
for identification of potential drug targets. For example, biochemical research studies established
overactivation of the JAK-STAT signaling pathway as the culprit behind autoimmune diseases such as
psoriasis and arthritis, opening the door to the development of a number of drugs (Tofacitinib, Upadacitinib,
Fedratinib) that target this pathway, specifically cell membrane proteins such as JAK1-3 and TYK26.

Given that drug discovery is an expensive process in terms of both money and time, easily costing over 1
billion U.S. dollars and a decade or more to take a drug from research and development (R&D) to the
market7, rigorous validation of potential drug targets is essential to minimize the risk of failure in the later
stages of drug development after enormous financial and temporal resources have already been invested.
Studies indicate that the high failure rate associated with drug development is largely due to improper target
selection8, highlighting the critical need to ensure that small molecules that bind a particular target will cure
or alleviate the associated disease in patients. Various biochemical approaches can be used for target
validation. For example, in in vitro experiments, the effect of inhibition of a candidate target can be studied
by selectively degrading the mRNA coding for that target using RNAi technology. Similarly, in in vivo
experiments, transgenic animals with modified candidate target genes can be used to model whether the
desired phenotype would be achieved by targeting the candidate with small molecules.

At the target identification and validation stage, computational methods are employed in concert with
bioinformatics tools to analyze biological datasets. Technological innovations are fueling the ability to

3

generate massive genomic, proteomic, and metabolic datasets, and the availability of such datasets in the
published literature is growing rapidly. The scale of such data overwhelms the capacity of manual analysis
and has necessitated the development of novel bioinformatic and computational methods to efficiently
analyze the raw data and extract key information for target identification9. An example is the use of in silico
mining methods by A. S. Perry et al. to identify genes downregulated in prostate cancer in the Expression
Atlas database10, leading to the identification of IGFBP3 as a novel target of methylation in prostate
cancer11. For more examples and further introduction of data mining methods that have been applied to
target identification, refer to the references12,13.

Of note, not all proteins found to be associated with a particular disease are suitable drug targets. Beyond
its biological role in the occurrence of disease, a candidate target must also be accessible to small
molecules. For example, the protein should have a well-defined active site that can be accessed and bound
by small molecules in a way that elicits the desired biological response. However, benefiting from new
techniques, many targets that were once considered “undruggable” have become druggable. For example,
completely sidestepping issues with small molecule binding, proteolysis targeting chimeras (PROTACs)14
can be used to degrade a target proteins to achieve therapeutic effects. Although such techniques have
shown promise, identification of small molecule inhibitors or activators remains the backbone of drug
discovery efforts. Thus, in this thesis, I will focus on discussing the computational methods and tools
designed for discovering small molecule drug candidates.

1.1.2 Hit Identification

Following identification and validation of a drug target, the hit identification stage aims to find a ‘hit’
compound that has relatively good binding affinity, typically on the micromolar scale or better, for the drug
target. Although the binding affinity is the first property to consider when searching for a hit, there are many
other important pharmacokinetic properties such as ADMET (absorption, distribution, metabolism, excretion,
and toxicity) that must be taken into account to evaluate whether a compound is a good potential drug
candidate. After analyzing the properties of a long list of approved drugs, Lipinski et al. proposed the
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famous ”Rule of Five”, which is a set of criteria that can be used to evaluate the potential of a small molecule
to be a successful drug candidate. The criteria comprise limits on the number of hydrogen bond donors and
acceptors, molecular mass, and octanol-water partition coefficient15.

Traditionally, to find active compounds for novel targets with no known ligands, high throughput screening
(HTS) has been used to screen large compound libraries against the target16. HTS usually involves
preparation of samples and compounds libraries, setup of automated equipment for the assay, and data
acquisition. In modern drug discovery projects, 10,000 to 100,000 compounds17 are usually screened per
day, necessitating minimization of manual work and reagent cost through automation and miniaturization
(e.g., by assaying one compound per well in 384-well plates with 50 µL reagent per assay. Although HTS
can be a powerful tool for uncovering compounds that bind to a target with appropriate strength, it bears
much of the responsibility for high costs and low efficiency in the drug discovery process18.

Fueled by increased accessibility of computing power and advances in chemical modeling, a variety of
computational methods have been developed to increase the efficiency and decrease the cost of identifying
hit candidates. In classical computational chemistry, the atoms of the target receptor and compounds can
be modeled as spherical balls, with the forces between different atoms governed by Coulombic and
Lennard-Jones interactions. The binding strength of a compound to a target can be estimated by modeling
these interaction forces. Using computational methods to screen compound libraries before conducting
traditional HTS could significantly reduce the cost, as a large number of inactive compounds can be
removed from consideration. Given the practical importance of virtual screening, developing effective virtual
screening methods is one of the central interests of computational chemists. I will discuss virtual screening
methods in more detail in Chapter Two.

1.1.3 Lead Optimization
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Once compounds that achieve the desired binding affinity for the drug target have been identified, lead
optimization is undertaken to further improve binding affinities and other pharmacokinetic and
pharmacodynamic properties, including selectivity and ADMET.

In the lead optimization stage, structure-activity relationships (SAR) are probed to improve the binding
strength and selectivity of the lead candidates for the drug target. The primary task in SAR is to understand
how the functional groups in the compounds contribute to their binding strength or selectivity so that they
can be rationally modified to improve these properties. Take Quantitative SAR (QSAR) for example. In
QSAR, binding affinity data from experimental assays are used to build a model for quantifying the
contribution of different functional groups to the target binding affinity. A QSAR study generally include two
steps: 1) extracting descriptors from the compound structures, and 2) mapping the descriptors to the activity
using a quantitative model. These two steps are iterative, as descriptors can differ based on the type of
activity and the effect of each descriptor on the activity is usually unknown. Although QSAR models have
achieved modest success in drug discovery, a common criticism is that they tend to oversimplify the
interactions between the ligand and receptor; therefore, expertise from medicinal chemists is still needed
to validate the generated QSAR models. Several reviews that provide a more detailed overview of how to
build QSAR models are referenced19,20.

A more recently developed computational tool for lead optimization is relative binding free energy (RBFE)
calculation. Building upon physics-based molecular simulation and statistical mechanics, REFE calculates
the binding free energy differences for a series of structurally similar compounds, thereby providing
invaluable guidance for synthetic chemists to optimize the lead experimentally. It has been argued that with
careful system preparation and a well-designed protocol, RBFE can achieve sufficient accuracy to facilitate
lead optimization. A more detailed theoretical and technical overview of RBFE can be found in the
referenced review21.

1.1.4 Preclinical Development
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Before testing a drug candidate in human subjects, researchers must confirm it will not cause serious harm
to the human body. The primary aim of preclinical development is to collect and organize such information
about the drug candidate in the form of an Investigational New Drug (IND) application for filing with the FDA.
The IND application requires the sponsor to submit results of animal pharmacology and toxicology studies
to assess whether the drug candidate is reasonably safe; manufacturing information to assess whether the
drug sponsor can produce drug batches of adequate consistency; and a clinical study plan to assess
whether the planned clinical studies are well designed. In preclinical research, animal models such as mice
are used to investigate the pharmacokinetics, toxicokinetics, and metabolism of drug candidates in vivo
with the aim of producing convincing evidence that 1) the compound is reasonably safe for trials in humans,
and 2) the compound exhibits pharmacological activity that justifies commercial development. To prevent
issues with IND approval, sponsors often arrange pre-IND meetings with FDA regulators to solicit their
comments on upcoming IND candidates.

1.1.5 Clinical Trials

After rigorous studies have been conducted in laboratory using animal models to demonstrate the
effectiveness and safety of a drug candidate, and after the IND has been approved by the FDA, clinical
trials in human subjects can officially begin. Due to the high cost of clinical trials, only the most promising
compounds make it to the clinical trial stage, while others with less desirable properties such as off-target
effects, high toxicity, and low solubility are relegated to the discard pile.

According to the FDA website, clinical trials are divided into four stages distinguished by their purposes and
sample sizes. In Phase 1 clinical trials, a small number (about 20 to 80) of volunteers are recruited to study
dosage and identify any associated side effects. During Phase I studies, researchers aim to gather
information that will help them determine the optimal dosage to maximize therapeutic benefits without
inciting intolerable side effects. Approximately 70% of drug candidates move on to Phase 2, whose primary
goal is to test the efficacy of the drug candidate. In the Phase 2, up to several hundred people with condition
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that the drug is meant to treat are recruited to study the drug’s therapeutic effect. Additional safety data are
also collected, and the protocols for the next phase are designed based on the data collected. For drug
candidates that move on to Phase 3, a larger number of volunteers—from several hundred to several
thousand—are recruited to further test the drug’s efficacy and monitor for possible adverse reactions. After
passing Phase 3 and receiving FDA approval, a new drug enters Phase IV, at which time the drug goes to
market and is available for doctors to prescribe to patients. The primary goal in Phase IV is to look for other
long-term effects of the drug such as the quality of life, cost effectiveness, and safety. Although FDA
approval and entrance to the market generally mark a drug as a success, the full range of side effects is
sometimes not revealed until a drug has been widely administrated to a more diverse population for a long
period of time. If severe side effects emerge after approval, the FDA may recall the drug to protect the
public.

1.2 Computer-Aided Drug Discovery

The concept of computer-aided drug discovery/design (CADD) was first introduced in the 1980s by an
article published in the journal Science that proposed that the shapes of the receptor and drug were
important factors in determining the activity of the drug and demonstrated how the receptor-drug structures
could be modeled on a computer22. With increased access to computing power and the development of
theory and software for molecular modeling, CADD has enjoyed rapid progress over the past four decades.
The primary goal of CADD is to increase the efficiency and probability of finding promising drug candidates
while decreasing the associated cost.

The typical roles of CADD in drug discovery include: 1) identification of compounds in a compound library
that could potentially bind the drug target (hit identification), and 2) rational modification of the lead
compound to enhance its pharmacokinetic properties, including binding affinity and ADMET.

For hit identification, computational methods such as molecular docking, ligand similarity search, and
scaffold hopping are used to separate potential binders from non-binders in virtual compound libraries.
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Widely used virtual libraries include the ZINC Database23 and Enamine REAL Database24, each of which
comprises millions of synthetically feasible or purchasable small molecules. Because of the requirement for
speed, computational tools at this stage usually do not have high accuracy, but they are able to provide a
narrower pool of compounds for validation by more sophisticated and expensive computational methods in
the following stages, thus saving time and money. In Chapter Two, we will expand our discussion of virtual
screening methods.

For lead optimization, the atomic interactions between the protein and ligand are closely examined. If the
crystal structures of the protein and ligand are available, possible non-covalent interactions such as
hydrogen bonds, ionic interactions, hydrophobic interactions, cation-π interactions should be identified and
taken into consideration in the optimization process. Importantly, water molecules around the binding site
should also be considered, as many studies have shown that optimized water interaction networks can
increase the protein-ligand binding strength25–27. Analysis of water thermodynamics using inhomogeneous
solvation theory is introduced in Section 3.1. To rationally modify the lead compound, an accurate model
of protein-ligand binding is paramount. Once the crystal structure of the protein-lead complex has been
solved experimentally, further chemical modifications to the ligand are made based on the interactions
presented in the protein-ligand crystal structures as it is assumed that small chemical modifications should
not significantly change the overall binding configurations. In cases where the bound structure has not been
experimentally determined, molecular docking can be used to predict binding poses as a starting point, and
more expensive computational tools such as molecular dynamics can also be applied to refine the predicted
binding poses. If the crystal structure of a protein target is not available, computational methods such as
homology modeling and deep learning-based structure prediction can be applied. However, 3D structure
prediction is a challenging task itself. Although there has been remarkable progress in the field of deep
learning, as exemplified by programs such as AlphaFold28, more investigation is needed to determine how
predicted protein structures can be used in drug discovery.

Fueled by the development of new scientific methods, especially force field and sampling methods, and
increases in computing power, free energy calculations are becoming a routine tool in lead optimization.
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The calculated free energy difference between two states can be used to estimated small molecule transfer
free energies, absolute binding free energies, and relative binding free energies. Depending on whether
the intermediate states are simulated, methods for free energy calculation can be categorized as end-state
methods (such as LIE29, MM-PB(GB)SA30) or alchemical pathway methods (such as FEP31, TI32, BAR33,
WHAM34). Typically, alchemical pathway methods are considered to be more accurate than end-state
methods given that they are more theoretically rigorous and have higher sampling demands. For a more
detailed introduction to free energy calculation methods, we refer readers to several excellent reviews21,35,36.
In Section 3.2, we will discuss the theory behind free energy calculation by TI. Figure 1 outlines popular
methods used in CADD; a more detailed description of these methods can be found in the referenced
publications37–39.

Figure 1. CADD methods used in drug discovery.
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Chapter Two: Machine Learning for Virtual Screening
2.1 Introduction to Virtual Screening
Virtual screening plays a significant role in facilitating the drug discovery process and lowering the
associated cost. The primary goal of virtual screening is to find compounds that bind to a drug target with
reasonable binding strength without running large-scale experimental assays (such as HTS). For virtual
screening, computational modeling is applied to analyze how the compounds interact with a protein target
and estimate how strong the interactions are. Only the compounds that are estimated to have strong binding
affinity for the drug target and suitable pharmacological properties will be synthesized for experimental
validation, thereby substantially increasing the efficiency of the drug discovery process and reducing the
associated cost. Based on whether the target structure is used in modeling, virtual screening methods can
be broadly categorized as ligand-based virtual screening or structure-based virtual screening.

2.1.1 Ligand-based Virtual Screening

Ligand-based virtual screening uses the chemical and structural information of known actives to identify
new actives and is agnostic to the target protein structure. The hypothesis underlying ligand-based virtual
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screening is that compounds that have similar shape and chemical composition are likely to bind the same
target, a concept supported by a survey of targets in the Protein Data Bank (PDB) database40.

A typical ligand-based virtual screening method includes two major steps: 1) establishment of molecular
descriptors to represent geometrical and chemical information and 2) measurement of similarity based on
these descriptors. In terms of geometrical descriptors, Putta et al. published an excellent review of methods
for representing molecular shapes based on moment, gnomic, volume, and/or surface area41. In addition,
Nicholls and Grant introduced molecular shape and electrostatic field descriptors and applied them to the
OpenEye Rapid Overlay of Chemical Structures (ROCS) platform42. A more comprehensive introduction to
ligand-based methodologies can be found in a great review by Florence et al.43. Here, I will limit discussion
to fingerprint-based approaches, scaffold hopping, and pharmacophore modeling as these are among the
most widely used ligand-based methods in modern drug discovery.

Fingerprint-based similarity search

In computational chemistry terms, a fingerprint is an abstract representation of the chemical and structural
features of a molecule. The bit string fingerprint representation encodes the presence or absence of
structural fragments, connectivity patterns, and pharmacophore arrangements in a molecule44,45.
Depending on how the molecular features are encoded in the bit array, there are two types of 2D fingerprints
that are widely used in ligand similarity search: circular fingerprints and hashed fingerprints.

Circular fingerprints represent the molecular structure by considering the neighbors of each atom. A widely
used type of circular fingerprint is the extended-connectivity fingerprint (ECFP). ECFPs are derived using
a variant of the Morgan Algorithm46. Based on the identity of neighbor atoms surrounding a center atom, a
numeric identifier is assigned to the center atom to represent its chemical environment. Due to the way they
are implemented, ECFPs can be calculated rapidly, do not require predefined substructures and can be
easily interpreted for substructure analysis. Rogers and Hahn published a detailed introduction to the
generation of ECFPs and the molecular features they encode, such as element identity, number of
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neighbors, charge, donor/acceptor status, aromaticity, basicity, and acidity47. An alternative to circular
fingerprints, hashed fingerprints are generated by identifying all possible fragments in a molecule that are
not bigger than a certain size and then converting these fragments into numeric values using hash
algorithms. A widely used type of hashed fingerprint is the daylight fingerprint48. Besides circular and
hashed fingerprints, there are other types of fingerprints that require predefined libraries of substructures.
A binary array is used to encode the fragment composition of a molecule, with 1 and 0 respectively
representing the presence or absence of a substructure. Examples are MACCS49 and PubChem
fingerprints50, which respectively use predefined libraries of 960 and 881 fragments to represent the
chemical composition of molecules.

Figure 2. Schematic representation of a binary 2D fingerprint.
A molecule is examined by the fingerprint generation algorithms to check the presence (labeled as 1) or
absence (labeled as 0) of predefined substructures. Adapted from Gortari et. at50.

There are many metrics to quantify the similarity or distance between two molecules based on their
fingerprint representations; examples are shown in Table 1. Distance and similarity can be interconverted
using Eq. 1. Bajusz et al. conducted a comprehensive comparison of these metrics and found that the
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Tanimoto, Dice, and Cosine coefficients all achieve good performance in similarity measurements51. A
variety of fingerprint and similarity calculation tools are available in the RDKit open source package52.

Table 1. Metrics for fingerprint similarity and distance calculation.
Metric

Continuous variable

Manhattan distance

D A,B = ∑ | xiA − xiB |

Binary variable

N

D A,B = a + b − 2c

i=1

N

∑ (x

DA,B =

Euclidean distance
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− xiB )2

i=1
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N

Cosine coefficient
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∑x

x

iA iB

i=1

N

∑ (x

N

iA

i=1

)2 + ∑ (xiB )2

S A,B =

c
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i=1

N

Dice coefficient

S A,B =

2∑ xiA xiB
i=1

N

∑ (x
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N

iA

)2 + ∑ (xiB )2

S A,B =

2c
a+b

i=1

N

Tanimoto coefficient

S A,B =

∑x
N
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iA

x
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N

N

i=1

i=1

)2 + ∑ (xiB )2 − ∑ xiA xiB
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S A,B =

c
a + b− c

Eq. 1

S A,B =

1
1+ DA,B

Scaffold hopping
In contrast to fingerprint-based similarity search, scaffold hopping aims to discover compounds that have
different core fragments from known ligands but exhibit similar activities. There are two major cases in
which scaffold hopping is desirable: 1) the core fragments in known ligands have undesirable
physicochemical properties and are hard to optimize chemically, and 2) known ligands are patented, and
only compounds with novel scaffolds can be registered as new intellectual property. Pharmacophores and
shape-based approaches are widely used for scaffold hopping.

The International Union of Pure and Applied Chemistry (IUPAC) defines a pharmacophore as the ensemble
of steric and electronic features of a ligand that are necessary to ensure optimal intermolecular interactions
with the target and to trigger or block its biological function53. These interaction features include hydrogen
bond donors or acceptors, cationic atoms, anionic atoms, aromatic regions, and/or hydrophobic regions.
When the binding poses of ligands bound to the target are available, pharmacophore features can be
organized in 3D space based on the patterns that emerge from comparing the ligands. When the scaffolds
in known ligands are chemically distant but exhibit the same pharmacophore features, the scaffolds can be
swapped to generate new compounds with similar activity. Pharmacophore queries can also be extracted
from ligands in the form of fingerprints and be used to screen for compounds with similar pharmacophores
in chemical databases54.

When the molecular features of known ligands are difficult to extract, shape-based searching can be used
given the argument that it is the overall 3D shape of a compound rather than its individual features that
determines binding ability. When the protein-ligand binding structures are available, the 3D shapes of the
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ligands can be modeled and used to search for compounds with similar shapes. An widely used application
of shape-based search is OpenEye ROCS, in which molecular shape is approximated with Gaussian
functions centered on the atoms and mixed shape-electrostatic similarity scoring is employed to evaluate
3D shape alignments55,56.

2.1.2 Structure-based Virtual Screening

When the crystal structure of a drug target is available, its binding site can be modeled to predict interactions
between the drug target and ligands and identify compounds with strong binding affinity. Aided by advances
in X-ray crystallography, NMR, and cryo-electron microscopy, 177,910 protein structures, including
structures of 52,564 human proteins, have been deposited in PDB to date. Although structures in PDB can
provide key information for identifying potential ligands, the quality of a structure, especially in the ligand
binding site, must be considered before it can be applied to drug discovery projects. Issues such as incorrect
assignment of oxygen and nitrogen atoms57 and missing side chains on key residues must be addressed.
Warren et al, proposed a method based on electron density and ionization state for evaluating the quality
of a protein structure and identifying protein-ligand interactions58.

Molecular Docking
The most popular structure-based virtual screening method is molecular docking, which consists of two
steps: 1) pose generation and 2) pose scoring

Pose Generation
For pose generation, shape matching is one of the most basic and earliest algorithms. In shape matching,
the ligand is placed in the binding site such that the molecular surfaces of the ligand and receptor are
complementary. Many other pose sampling algorithms, ranging from stochastic search and incremental
search to molecular dynamics-based approaches, have been developed to sample possible poses. For
example, DOCK6 uses an “Anchor-and Grow” algorithm59, in which the largest rigid substructure of the
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ligand (the anchor) is identified and rigidly placed in the binding site while the flexible part of the ligand is
built into the anchor within the context of the receptor. In contrast, AutoDock60 uses a Monte Carlo random
search strategy in which the ligand is first placed into the active site in an initial configuration and then
manipulated by random translational and/or rotational movements to generate a new configuration in an
iterative process; each configuration is evaluated and the best is selected by the metropolis criterion. A
good overview of configuration search algorithms can be found in a review by Kitchen et al61.

Pose Scoring Using Scoring Functions

The primary goal of a scoring function is to evaluate how strongly the ligand binds to the receptor in each
pose generated in the first step of molecular docking. A scoring function that can efficiently and accurately
evaluate a ligand configuration is fundamentally important to successful docking. An efficient scoring
function is required to rapidly rank the many ligand configurations that are generated during the pose
sampling step. Accuracy is essential to prioritizing “good” poses over poor ones; otherwise, the poses
selected may not reflect the correct poses, and true ligands may even be missed completely if the scoring
function fails to identify reasonable poses. Scoring functions used in current docking programs can be
classified into four types: 1) force field-based scoring functions, 2) empirical scoring functions, 3)
knowledge-based scoring functions62, and 4) machine learning-based scoring functions.

Force field-based scoring functions. Force field-based scoring functions estimate binding strength by
calculating the energy of a protein-ligand binding configuration based on Van der Waals (VDW) interactions,
electrostatic interactions, and bond stretching/bending/torsional potential energy. To calculate these atomic
interactions, force field parameters are often taken from molecular dynamics simulation force fields. For
example, the Leonard-Jones and charge parameters in the DOCK program are taken from Amber force
fields63,64. For example, Amber Score in DOCK6 calculates binding energy using the eq. 2.

Eq. 2

Ebinding = Ecomplex − Ereceptor − Eligand

17

For each species (receptor, ligand, or complex),

E

can be written as

Eq. 3
polar
non− polar
E = E MM + Esolv
+ Esolv
polar

Where Esolv
Model65,

is the electrostatic component of solvation energy estimated by the General Boltzmann

non− polar
is the non-polar part of the solvation energy estimated by the solvent accessible
Esolv

surface area term66, and

E MM

is the molecular mechanics energy and can be decomposed into the

potential energy from bonds, angles, and dihedrals and the non-bond energy from VDW and electrostatic
interactions as in eq. 4. The bond, angle, dihedral, Lennard-Jones, and charge parameters are ported from
the Amber force field.

Eq. 4

E MM = Ebond + Eangle + Edihedral + Evdw + Eelec
Due to its practical applications in drug discovery, studies to improve the accuracy of force field scoring
functions have been published by many different groups. For example, both DOCK and AutoDock
accounted for the solvation effect using inhomogeneous theory67,68; and other studies investigated adding
more terms to the binding energy; for example, MedusaScore69, Gold70, and AutoDock71 include hydrogen
bond contributions in their scoring functions.

Empirical scoring functions. An empirical scoring function estimates the strength of receptor-ligand binding
by summing up the contributions of a number of individual terms as shown in eq. 5

Eq. 5

ΔG = ∑Wi i ΔGi
i
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ΔGi

Where

represents different energy terms such as hydrogen bonding, desolvation, hydrophobicity and

so on and Wi is the weight of each contribution and is typically calibrated by fitting the calculated binding
energy with the experimentally determined binding affinity data. An example of an empirical scoring function
is ChemScore72, which considers contributions from ligand hydrogen bonds, metal ions, lipophilic effects,
and rotational bonds and calibrates the weights on each term using a set of 82 ligand-receptor complexes.
Another example is X-Score, developed by Wang et al. X-Score consists of four energy terms (VDW
interactions, hydrogen bonds, hydrophobic effects, and rotational bonds) with weights calibrated based on
a set of 200 protein-ligand complexes73. Following X-score, a new scoring function that includes steric
interactions, hydrophobic interactions, and hydrogen bonding was developed by Trott et al. and
implemented in AutoDock Vina74.

Knowledge-based scoring functions. The first knowledge-based scoring function was included in the
SMoG75 program by Dewitte et al. Further examples are PMF76, DrugScore77, and IT-Score78. Although
their technical details differ, they all follow the same principle of binding score estimation, namely the
summation of statistical potentials between the receptor and ligand as in eq. 6

Eq. 6

A=

ligand receptor

∑ ∑
i

ω ij (r)

j

where ω ij (r) is the distance-dependent potential between atom

i

and atom j derived from an inverse

Boltzmann analysis as in eq. 7:

Eq. 7

ω ij (r) = −k BT ln[g ij (r)] = −k BT ln[

ρij (r)
ρij*

]

where ρ ij (r) is the number density of the atom pair

i-

j at distance

r and

ρij* is the number density of

the atom pair in a reference state where the atomic interaction between the two atoms is zero. Compared
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to force field-based and empirical scoring functions, some have studies78,79 showed that knowledge-based
scoring functions might offer a good balance between accuracy and speed because the potentials are
extracted from the structures and less dependent on the training set.

Machine learning-based scoring functions. In contrast to the classical scoring functions inspired by the
physical principles that govern protein-ligand interactions, machine learning-based scoring functions,
instead aim to capture the intermolecular interaction features that determine binding implicitly from labeled
training data. It has been argued that machine learning scoring functions have advantages over classical
one because 1) machine learning scoring functions have neither fixed functional terms nor functional forms,
which are usually oversimplified models of binding forces and 2) machine learning-based scoring functions
do not have presumed assumptions and are capable of learning unknown features that determine binding
strength.

With the increasing availability of structural and bioactivity data, machine learning-based scoring functions
have garnered much interest. Many studies have reported that machine learning-based scoring functions
such as those based on random forest

80

and convolutional neural network81,82 algorithms outperform

traditional scoring functions . In Chapter Three, we will expand our discussion of the application of machine
learning to virtual screening and observe through the results of the first project of this thesis how biases in
the datasets used to train and test machine learning-based scoring functions can lead to misleading
conclusions.

Criteria for evaluating scoring functions

The three primary goals of scoring functions are identification of binding pose, prediction of binding affinity,
and enrichment of active compounds from virtual screening databases. Three popular matrices are used
to evaluate the success of a scoring function in achieving each of these goals on a test set for which the
ligands of the protein targets and their binding poses are known. The first is the RMSD matrix (eq. 8), which
is used to measure how well the scoring function identities the native pose.
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Eq. 8

1 n
⎡⎣(xiv − xiw )2 + ( yiv − yiw )2 + (ziv − ziw )2 ⎤⎦
∑
n i=1

RMSD(v, w) =

Here, v is the pose ranked most highly by the scoring function, w is the native binding pose determined
from the crystal structure of the protein-ligand complex, and n is the total number of atoms in the ligand. As
a rule of thumb, the scoring function is considered to have successfully identified the native pose if the topranked pose has a root-mean-square deviation (RMSD) of less than 2 Å from the native pose. The second
matrix is the Pearson correlation (eq. 9), which is usually used to measure the correlation between the
estimated binding affinities and the experimental affinity data.

Eq. 9
N

R=

∑( X

k

− X )(Yk − Y )

k=1

N

N

k=1

k=1

[∑ ( X k − X )2 ][∑ (Yk − Y )2 ]

Here, N is the total number of binding affinity data points;

Xk

and

Yk

are the calculated and experimental

binding affinities for the k -th data point, respectively; and X and Y are the arithmetic average values of
the calculated and experimental binding affinities, respectively. Binding affinity prediction is considered a
more challenging task than pose prediction because the affinity values in the database might have been
measured in different experimental conditions by different research groups. The third matrix is the receiver
operating characteristic (ROC) curve, which indicates the ability of the scoring function to select active
compounds over non-binding decoys. The ROC curve plots the true positive rate (TPR) versus the false
positive rate (FPR), which are calculated as in eq. 10 and eq. 11, respectively:
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Eq. 10

TPR =

TP
N active

Eq. 11

FPR =

FP
N decoy

Where

TP

N active

and N decoy are the total numbers of actives and decoys in the library, respectively. Quantitatively,

and

FP

are the number of true positive and false positive compounds, respectively, and

area under the curve (AUC) is used to measure the overall enrichment performance. An AUC of 0.5
represents equal selection of actives and decoys (random performance), and enrichment performance
increases as AUC approaches one. Figure 3 depicts three example ROC curves.

Figure 3. Three types of ROC curve.
dotted line = diagonal line，blue = good enrichment , orange = random enrichment, green = poor
enrichment overall but have good early enrichment.

Performance of classical scoring functions
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There are many excellent reviews and studies that have evaluated the performance of currently used
classical scoring functions83–85. Such scoring functions can usually provide reliable pose identification; for
example, Trott and Olson showed that Vina identifies the correct pose with a 78% success rate in a test
set74. However, despite considerable progress, the accuracy of classical scoring functions in predicting
binding affinity is generally not satisfactory86,87, preventing achievement of high enrichment performance.
For example, in DOCK6, the AUC for 38 targets in the Database of Useful Decoys (DUD) ranges from 0.29
to 0.96 with an average AUC of 0.685. There are two fundamental reasons underlying this suboptimal
enrichment performance. First, the forces that determine the binding affinity are not yet thoroughly
understood, meaning models used to estimate binding affinity in scoring functions may make inaccurate
assumptions. Second, scoring functions must simplify the terms contributing to binding affinity to meet
speed requirements; for example, entropy terms are neglected in scoring functions even though entropy is
fundamentally important to binding strength. Recently, machine learning-based scoring functions have
been developed to circumvent these limitations, and many have been reported to outperform classical
scoring functions80,88,89. Machine learning-based scoring functions and other applications of machine
learning to drug discovery will be discussed in the next sections.

2.3 Introduction to Machine Learning

Machine learning is a discipline that involves the use of algorithms to learn patterns from existing data and
then use the patterns learned to make determinations or predictions about new data without instructions
for making these predictions being explicitly programmed. Therefore, after assembly of a suitable dataset
for training an algorithm, the task of a machine learning programmer is to code algorithms that can learn
the appropriate features from the training data to perform the desired task rather than writing explicit rules
to carry out the task directly. Therefore, machine learning is generally useful for carrying out tasks for which
a large amount of data is available and for which the rules required to carry out the task are difficult to
program or even unknown. There are three steps in a machine learning task: 1) preparation of a relevant
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dataset, 2) selection of a machine learning model, and 3) training and validation of the trained model’s
performance. In following sections, I discuss each of these steps with a focus on the drug discovery process.

2.3.1 Dataset preparation

The power of machine learning approaches can only be unleashed when a large volume of high-quality
data is available for training. It is argued that machine learning projects are composed of 80% data collection
and preparation and 20% algorithm development. Andrew Ng, a pioneer in the machine learning field,
recently argued that “the machine learning community should be more data-centric and less modelcentric”90, invoking the vital importance of data quantity and quality to the success of a machine learning
project. An example of a good dataset leading to the successful application of machine learning is
ImageNet91, a database compiled by Feifei Li et al. for training algorithms for the identification of objects in
images. ImageNet contains 3.2 million high-quality images with 500-100 clean and full resolution images
per object and is considered to be the dataset that catalyzed research into machine learning for image
recognition; competitions—the annual ImageNet Large Scale Visual Recognition Challenge—were even
held to incentivize use of ImageNet to advance the field of image recognition by machine learning
approaches. Based in part on work this field, it is now widely recognized that for a machine learning model
to be successfully applied to real word problems, the data used to train the model should reflect the diversity
and complexity of the real world.

In the application of machine learning to drug discovery, the most relevant data are not images but rather
protein crystal structures and the binding affinities of compounds for their targets. Such data must be
generated by tedious experiments conducted by trained scientists, making them much more expensive and
time-consuming to obtain compared to data like images, voice samples, and handwriting samples. Thus,
although the remarkable successes that machine learning achieved in fields such as image and speech
recognition sparked many efforts to similarly revolutionize the drug discovery process through machine
learning approaches, the limited availability of relevant data and the noisiness of the data that are available
have hindered progress. Because of the high cost and labor barrier of generating data for drug discovery
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purposes, machine learning models for drug discovery are commonly trained by datasets comprising data
collected through the joint efforts of different groups from academia and industry rather than generated by
a single group using consistent protocols and experimental conditions. This requires that any entity aiming
to build a machine learning model for drug discovery have appropriate domain knowledge to be aware of
the noise and possible biases present in the dataset they are using so they can confirm their model learns
generalizable patterns in the dataset rather than artificial noise or biases associated with the data. In
Section 2.4, I will describe the results of our investigation into how artificial biases in a widely used training
dataset mislead machine learning models.

2.3.2 Selection of a machine learning model

Depending on their purpose and the data they are trained by, machine learning models are categorized
into supervised and unsupervised models. Supervised models are trained by labeled datasets and then
used to predict either the category a query falls into (classification) or the value of a continuous variable
associated with it (regression), while unsupervised models are used to cluster the data into different groups
based on intrinsic features of the data themselves. Figure 4 lists the many types of machine learning
algorithms for both supervised learning and unsupervised learning. An exhaustive introduction to each
model is outside the scope of this thesis; interested readers can refer to the referenced publication for a
useful resource in this regard92. In the following sections, I will discuss the three types of supervised models
that are used in this thesis and are also widely used in the drug discovery field.
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Figure 4. The classification of machine learning models.

K-nearest neighbor (KNN). KNN models perform classification or regression based on the neighbors of
each data point when the dataset is plotted in relevant dimensions (Figure 5). The principle is that data
points in the training set that are close to a new data point should be predictive of the new data point’s label
or value. Because of its ease of implementation and quick calculation time, KNN is widely used in the
recognition of handwritten digits and advertisement recommendation systems. For example, consumers
can be classified into different groups based on their purchase histories, and advertisement
recommendations for new consumers can be made based on the purchasing behavior of the group that the
new consumer belongs to.
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Figure 5. An illustration of a simple KNN model for classification.
The training data (orange triangles and green circles) are plotted in two dimensions. To determine the
identity of a new sample (the red square), the KNN algorithm checks the identity of its nearest neighbors
and assigns it the most highly represented identity, in this case an orange triangle.

There are two steps in a KNN algorithm-based prediction: 1) find the neighbors of the test sample 2) make
predictions based on the neighboring values. After the features (dimensions) of the training data have been
extracted and represented as mathematical values, the neighbors of a test sample are identified by
calculating the distance of training samples to the test sample. One of the most widely used equations for
identifying neighbors is the Euclidean distance (eq. 12):

Eq. 12
N

D( p,q) = ∑ (qi − pi )2
i=1

where p , q are two datapoints (the test point and a training data point) in a N dimensional space
constructed by the N features extracted from the data. There are many other algorithms that are
implemented in the scikit-learn Python package such as brute force, ball tree and KD tree; these can be
more efficient than Euclidian distance when the dimensionality is high or the sample size is large. During
the training stage, the best K value is determined by minimizing the losing function. During the test stage,
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the K samples that are closest to the test sample are identified as its neighbors, predictions about the test
sample are made based on majority or weighted vote of the K neighbor samples.

Support vector machine (SVM). SVM is another widely used machine learning algorithm in which a
hyperplane in an N-dimensional space is identified to separate the samples or datapoints into different
classes. The support vectors are datapoints that are close to the hyperplane and determine its parameters,
including orientation and position. During training, the hyperplane that allows for the maximum margin
between support vectors from different classes is identified using the loss function (eq. 13):

Eq. 13

L(w) =

1
N

N

∑ max(0,1− y [w

T

i

xi + b]) + λ || w ||2

i=1

where N is the number of support vectors in each dimension ( xi , yi ) and λ regulates trade-off between
increasing the margin size and ensuring that

xi

is on the correct side of the hyperplane (Figure 6).

Figure 6. An illustration of an SVM model.
A hyperplane (red line) is determined by SVM model by maximize the margin between support vectors in
the orange triangle category and the green circle category.
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As rule of thumb, SVMs are preferred when the datapoints have many features and are relatively small in
number. This is because when SVM is applied to a large number of training datapoints, over-fitting
commonly occurs.

Random Forest. Random forest is another popular machine learning algorithm for carrying out supervised
classification and regression tasks. During training, an ensemble of decision trees is constructed, and the
final output of the model is the majority vote or the average value of the decisions made by following these
trees. A decision tree is a flowchart-like structure that connects the root node to leaf nodes by a series of
internal nodes. The datapoint starts at the root node, and the internal decision flow is determined at internal
nodes that represent the features of the datapoint until a leaf node representing the final label awarded to
the datapoint is reached. Figure 7 is a simple example of a decision tree for whether an undergraduate
student should apply for PhD program.

Figure 7. An illustration of a decision tree.
A decision tree model to determine whether an undergraduate student should apply for a PhD program.
The root node (purple rounded rectangle) is connected to leaf nodes (ovals) by a series of internal nodes
(blue rounded rectangles). Decisions are made at each node based on the features of a datapoint until a
leaf node is reached.
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Convolutional neural network (CNN). CNN is a type of deep learning algorithm that has gained increasing
attention in recent years following its remarkable success in image and speech recognition. The algorithm,
inspired by an experimental study of the monkey striate cortex93, was first introduced in 1980 and consisted
of convolutional layers and downsampling layers. The first breakthrough in applications of CNN models
came in the 1990s, when Yann LeCun et al. published a study showing that CNN models can process input
features progressively by layer and that the resulting models can be used for robust handwriting
recognition94. The typical architecture of a CNN model consists of four different layers: the convolutional
layer, pooling layer, rectified linear units (ReLU) correction layer, and fully connected layer (Figure 8). The
convolutional layer consists of transformed features that are generated by calculating the convolutional
product of the features from the upstream layer using a filter. The pooling layer aims to reduce the size of
the features while preserving their important characteristics; for example, only the maximum values of each
region from the previous layer are preserved in the pooling layer. The ReLU correction layer acts as an
activation function that only keeps positive values from the previous layer and changes any negative values
to zero. The fully connected layer is always the last layer of the CNN model and uses a nonlinear
combination of the features from the last layer to produce the final output of the CNN model.

Figure 8. The architecture of a CNN model for image recognition.
The blue, orange, and red layers represent the convolutional layer, ReLU layer, and pooling layer,
respectively. The fully connected layer (green) is the last layer of the model.
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Different machine learning algorithms often have advantages over other models for specific tasks. For
example, CNN models have been shown to be superior to other algorithms for tasks such as image and
speech recognition. In the case of novel or complex tasks, a trial-and-error approach comparing the
performance of different types of machine learning models using the same training and testing dataset is
recommended. Although this seems like a daunting task, many open-source packages have user-friendly
command interfaces that facilitate development and comparison of machine learning models. For example,
scikit-learn and TensorFlow are among the most popular libraries for deploying and testing machine
learning models in Python.

2.3.3 Model training and validation

After the dataset has been curated and the model type has been chosen, the next step is to divide the
dataset into a training set and a test set for use in training the model and then testing its performance,
respectively. Both the training set and test set should appropriately represent domain of the task for which
the model is being developed. One of the most widely used approaches is the k-fold cross-validation
method, in which the dataset is shuffled randomly and divided into k groups, with the kth group used as test
set and the remaining k-1 groups used to train the model. During the training stage, the model automatically
optimizes its parameters to minimize the loss function using optimization methods such as random search,
grid search, and gradient-based optimization
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. The goal of training is to allow the model to learn the

patterns present in the training set so it can generalize them to new data in the test set and ultimately
perform well when faced with real-world data, as well. However, it should be kept in mind that a trained
model that performs well on a training set may not necessarily perform well on a test set due to overfitting,
and a model that performs well on both training and test sets may not necessarily perform well on data
collected from the real world, especially when the dataset used to train and test is limited in some way that
prevents it from fully covering the problem space. In the next section, I describe the results of our study
showing how biases present in the dataset can mislead machine learning models.
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2.4 Application of CNN for virtual screening using DUD-E
2.4.1 Significance

Machine learning-based scoring functions for virtual screening have garnered extensive attention following
reports of their improved performance over classical physics-inspired scoring functions. At the time when
this project was initiated, efforts to further improve machine learning-based scoring functions were focused
on two areas: 1) development of methods able to better represent protein-ligand features, and 2) design of
novel models that learn from these features. After CNNs were shown to achieve remarkable success in
image and speech recognition, many independent groups reported not only that CNN models could also
be applied to virtual screening, but also that such models achieved unpreceded high performance. However,
in all the published studies up to that time, water features were neglected in the modeling of protein-ligand
binding even though they are known play essential roles in such interactions. Our initial hypothesis was
that adding water features to the data used to train CNN models for virtual screening would further improve
their performance.

In our study, we first showed that adding water features did not improve the performance of a CNN model,
contrary to our initial hypothesis. However, we noticed that the performance of the model was already very
high. Further investigation revealed that the source of this ultra-high performance was not successful
learning of important protein-ligand interaction features, but rather learning of biases present in the dataset
we used for training and testing, the popular benchmark DUD-E. Based on our results, we concluded that
models trained by protein-ligand conformations may learn from biases in the composition of the ligand pool
rather than from features of the target protein and/or its interaction with ligands. We also developed
methods to test the reliability of a model, including investigating whether the model is sensitive to ligand
pose and whether the model can perform well on a more challenging dataset like the actives as decoys
(AD) dataset we constructed in this study. Following its publication in 2019, our study has been widely cited;
we are pleased to see that our study has contributed to the machine learning-based virtual screening field
in three different ways: 1) The community has become more aware of biases inherent to the DUD-E dataset,
which will help prevent misuse and erroneous conclusions. New efforts have been launched to construct
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new datasets that address the bias we demonstrated (unmatched properties, DUDE+). 2) More rigorous
tests such as use of the AD dataset we constructed in our study are now being conducted to validate the
reliability of models. 3) Most importantly, the results of our study along with other independently conducted
studies suggest that caution should be taken in interpreting the performances of machine learning-based
models, as high performance may be due to biases in the dataset rather than learning of meaningful
information that can be reliably generalized to real-world drug discovery scenarios.

2.4.2 Abstract

Recently much effort has been invested in using CNN models trained on 3D structural images of proteinligand complexes to distinguish binding from non-binding ligands for virtual screening. However, the dearth
of reliable protein-ligand x-ray structures and binding affinity data has required the use of constructed
datasets for the training and evaluation of CNN molecular recognition models. Here, we outline various
sources of bias in one such widely used dataset, DUD-E. We have constructed and performed tests to
investigate whether CNN models developed using DUD-E are properly learning the underlying physics of
molecular recognition, as intended, or are instead learning biases inherent in the dataset itself. We find that
superior enrichment efficiency in CNN models can be attributed to the analogue and decoy bias hidden in
the DUD-E dataset rather than successful generalization of the pattern of protein-ligand interactions.
Comparing additional deep learning models trained on PDBbind datasets, we found that their enrichment
performances using DUD-E are not superior to the performance of the docking program AutoDock Vina.
Together, these results suggest that biases that could be present in constructed datasets should be
thoroughly evaluated before applying them to machine learning based methodology development.

2.4.3 Introduction

Virtual screening plays an essential role in lead identification in the early stages of drug discovery96,97.
Accurate lead identification can dramatically reduce the time and costs associated with experimental assays.
Therefore, developing computational tools that can identify lead compounds with pharmacological activity
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against a selected protein target has been a long-standing goal for computational chemists. A number of
structure-based docking tools that aim to predict ligand binding poses and binding affinities have been
developed and have enjoyed moderate success over the last three decades59,68,74,85,98,99.
Inspired by the success that deep learning has achieved in speech and image recognition100,101, many
groups have sought to apply deep learning methodology to protein-ligand binding prediction81,82,102–107 . Of
these, the grid-based CNN approach has been reported to have promising performance81,82,103. The
approach constructs a 3D grid of atom type densities from the protein-ligand structure in the binding site.
When training a virtual screening model, these grids are fed into the model, which automatically optimizes
its parameters to minimize a loss function whose value reflects the model’s ability to distinguish between
binding and non-binding compounds in the training set.
While CNN algorithms have existed for some time108,109, the recent resurgence and success of CNN-based
methods has widely been attributed to increased computational power and the development of large, highlycurated datasets91. It is generally believed that in order to implement CNN-based models in virtual screening,
large and diverse training sets and independent test sets are required to effectively train and objectively
evaluate the models.

DUD-E contains a large number of experimentally verified actives and property-matched decoys and has
been widely utilized to train and test machine learning models and compare their performance with that of
simple docking tools110–112. In many CNN-based virtual screening studies, it is typical to see models achieve
an area under the ROC curve greater than 0.9 for many targets from DUD-E81,82,104. Although some studies
have indicated that DUD-E may have limited chemical space and issues with analogue bias and bias
resulting from the decoy compound selection criteria113,114, it has not been clearly elucidated how these
potential biases affect CNN model development and performance.

A perceived advantage of CNN-based virtual screening approaches over more traditional approaches such
as physics-based empirical scoring is that, rather than requiring manual tuning of weights and terms of a
scoring function, CNN models can automatically learn the features that determine binding affinity between
a ligand and its protein target. However, the main disadvantage of complex machine learning models such

34

as CNN is that it is unclear what features of a dataset the model is prioritizing in making its binding
assessments. In a traditional parameterized scoring function, each term has a physically meaningful
interpretation (H-bond and hydrophobic contacts, ligand desolvation, etc.) and the importance of each term
can be assessed by their relative weights. In machine learning approaches, there are no such easily
interpretable terms, and it is difficult to assess what the models are actually learning.

To investigate the causes that lead to the high performance of CNN-based virtual screening, we define
three sources of information that the models can learn from. 1) Protein-ligand interactions: It is widely
believed that the physics that govern molecular recognition will apply to novel targets and drug candidates.
A hope for the machine learning-based approach is that models will learn the essential physics of molecular
interactions and therefore be applicable to new targets and the exploration of a novel ligand chemical
space. 2) Analogue bias: Binders of the same target, homologous targets, or targets with similar
functionality are thought to be correlated in chemical space. Models that learn these correlations could be
applied to find additional compounds that are similar to existing known binders of such targets. 3) Decoy
bias: For each target in DUD-E, decoys were selected by the authors with the criteria that the decoy ligands
have similar physical properties to the actives but differ topologically. However, this might lead to the decoys
being distinguishable from the actives by patterns resulting from the selection criteria. A model that learns
such patterns can distinguish decoys from actives only when the decoys fit the biased feature pattern and
would likely not be applicable to the prospective identification of novel compounds.

In the following work, we carefully construct training and test set combinations that are designed to isolate
or minimize the contributions of each of these biases. We find that the high performance of CNN models
trained on DUD-E is not attributable to having learned the features of protein-ligand interactions but rather
to analogue and decoy bias inherent in the DUD-E dataset. We show that it is incorrect to infer that a model
has successfully learned protein-ligand interactions solely on the basis of its high performance on a test
set. Due to the hidden biases in the DUD-E dataset that we describe in this work, one should be very
cautious when using DUD-E for machine learning based methodology development.

2.4.4 Methods
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Preparation of model input data
The CNN model requires as input ligands posed in a protein-binding pocket with each ligand marked as
active or inactive. In this work, we used the complete set of proteins from the DUD-E dataset, which is one
of the most widely used datasets used to develop and validate virtual screening approaches. The dataset
consists of 102 targets, each of which has a group of experimentally tested active molecules and propertymatched decoys. In total, it contains 22,886 actives and over a million decoys110.

Most of the actives in DUD-E do not have crystal binding poses. We generated poses for all the actives and
decoys in the training and test sets using the smina implementation of AutoDock Vina74,115. All compounds
are docked against the reference receptor within an 8 Å cubic box centered around a reference ligand. The
docked data can be found in the supporting materials of this thesis. In this study, only the top-ranking pose
as scored by Vina for each active and decoy was used as input for the CNN model.

Training and test set preparation
Training and test subsets of the DUD-E dataset were constructed in several different ways.

Single target CNN model
To build the single target CNN model, for each target, we randomly selected half of the actives for training
and used the remaining half for model evaluation. To reduce the training time and partially compensate for
the imbalance in the number of actives and decoys, for each target, we randomly selected 1000 decoys
and used 500 for training and 500 for testing. See Figure 9A.

Multi-target CNN model
To build the multi-target CNN model, we trained on a subset of protein targets and tested on the remaining
protein targets. The models were trained on half of the actives and 500 randomly selected decoys for each
target in the training subset. See Figure 9B.
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Figure 9. Data preparation for model training and testing.
The training set and test set for (A) the single target CNN model and (B) multi-target CNN model. Blue
denotes actives and yellow denotes decoys.

Actives as decoys dataset
The Actives as Decoys (AD) dataset was designed to minimize the decoy bias introduced by the selection
criteria in the construction of the DUD-E dataset. Instead of using the DUD-E decoys, the AD (actives as
decoys) dataset uses the active compounds of other proteins as the decoys for each target. The DUD-E
dataset is composed of 102 targets each of which has a set of active and inactive compounds. For each
protein target, we docked (using Vina) all of the active compounds from the other 101 DUD-E proteins to
that target. For example, for target AA2AR we took the actives of each of the other 101 proteins from the
DUD-E dataset (ABL1, ACE, ACES, …) and docked them to AA2AR. For each of the 101 proteins, we rankordered their respective actives based on their predicted binding affinity (returned by Vina) to the target
(AA2AR in this case) and chose the top 50 compounds. We compiled these compounds to create a decoy
dataset for the target (AA2AR in this case). If the number of actives for a protein was less than 50, then all
compounds were used. The AD dataset for all 102 targets can be found in the supporting materials of this
thesis.
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Model training
CNN model
Our CNN models were defined and trained by the Caffe deep learning framework; the model architecture
is as previously described. The source code can be found at https://github.com/gnina/gnina. Briefly, the
binding complex is transformed into a grid of atomic densities. The grid is 24 Å per side and composed of
48 * 48 * 48 voxels in 0.5 Å resolution centered on the ligand binding site. Each voxel has 39 channels in
total: 35 channels of atom density information corresponding to 16 protein atom types, 19 ligand atom types
(Table S1), and, optionally, 4 channels for water thermodynamic information computed by GIST. Water
thermodynamic information was not part of the originally published CNN model. It was added here to
explore whether adding solvation effects to the protein-ligand system improves the performance of the CNN
model. We built three kinds of CNN models: 1) receptor-ligand-water model, 2) receptor-ligand model and
3) ligand-only model, distinguished by the binding information used for model training. The receptor-ligandwater model uses all 39 channels of information, and the receptor-ligand model uses just the information
from the 35 atomic densities. In the ligand-only model, the original receptor is replaced by a single dummy
atom; therefore, the atomic density values from the 16 receptor channels all equal zero, and only the 19
channels from the ligand are used. As illustrated in Figure 10. the input tensor that consists of a specific
number of channels plus a label of 1 denoting an active compound or 0 for an inactive compound is then
fed to the model, which consists of three units of Pooling (2*2*2 filter)- Convolutional (3*3*3 filter)-ReLU
layers and a single fully connected layer that outputs the binding prediction. During training, we used a
learning rate of 0.01, a momentum of 0.9, an inverse learning rate decay with power = 1 and gamma =
0.001, and a weight decay of 0.001. In each training iteration, we used balanced actives and decoys with a
batch size of 10 for 2000 iterations. We manually checked that all models qualitatively converged at the
end

of

the

training.

The

protocol

for

training

the

CNN

(https://www.protocols.io/view/train-cnn-model-using-gnina-3rngm5e).
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Figure 10. The architecture of the CNN model.
Each unit consisted of three layers, Pooling, Convolutional and ReLU. The yellow bar labeled FL is the fully
connected layer. Further details about the CNN model hyperparameters can be found in reference116.

KNN model
KNN classification predicts a ligand’s label (binder or nonbinder) based on the majority vote of its K nearest
neighbors in a defined feature space. Here, the input for the KNN model were “RDKit” fingerprints (2D)
generated by the RDKit python package (http://www.rdkit.org, version 2018.09.1). The bit size for the “RDKit”
fingerprints is 2048, and the script that was used to output the fingerprints can be found in the supporting
materials of this thesis. To compare the KNN model’s performance with that of the ligand-only CNN model,
the same training and test sets were used for each target. The python scripts we used for training KNN
models can be found in the supporting materials of this thesis.

GIST-based water analysis
To investigate whether adding water information to the protein-ligand binding complex could improve the
accuracy of binding prediction, we applied GIST from AmberTools to map out the water properties by
analyzing the water trajectory produced by molecular dynamic (MD) simulation117. Protein structures were
downloaded from PDB118, and proteins were prepared using the default parameters in the Maestro Protein
Preparation Wizard (Schrödinger)119. As we were interested in the solvation of the binding sites,
membranes were not modeled for trans-membrane proteins as they were distal to the active site. The MD
simulations were conducted with Amber16 using the ff14SB forcefield120,121. A subset of prepared apo-
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proteins, listed in Figure 11, were placed in a box of OPC water such that all protein atoms were at least
10 Å from the periodic boundary of the box. The equilibration run consisted of two minimizations of up to
20,000 cycles followed by a 240 ps run at constant volume where the temperature of the simulations was
raised from 0 to 300 K and protein heavy atoms were harmonically restrained with a force constant of 100
kcal/mol•Å2. Next, we performed an additional equilibration MD run of 20 ns under NPT conditions with the
100 kcal/mol•Å2 gradually reduced to 2.5 kcal/mol•Å2 in the first 10 ns and held constant for the last 10 ns.
Production simulations were then performed for 100 ns in NVT conditions at 300 K, with heavy atom
restraints of 2.5 kcal/mol•Å2. The 100 ns trajectories were then processed by AmberTools cpptraj-GIST with
a grid spacing of 0.125 Å3, centered on the ligand binding sites to produce solvation thermodynamic maps.
The resulting GIST maps of the solute-water enthalpy (Esw), water-water enthalpy (Eww), translational
entropy (TStrans), and orientational entropy (TSorient) were added as the 4 additional channels to the original
35 protein-ligand channels to train the protein-ligand-water models.

2.4.5 Results
Adding water information does not improve the performance of the protein-ligand CNN model
Using the single target CNN model approach, we independently trained the protein-ligand and proteinligand-water CNN models on 10 targets from the DUD-E dataset. Originally, we hypothesized that adding
water information channels could improve virtual screening performance as shown in previous work by
Balius et al., in which adding water energy terms to scoring functions improved the virtual screening
performance of DOCK3.7. As shown in Figure 11, the receptor-ligand CNN model achieved high
enrichment efficiency (0.98 ± 0.02), which is consistent with the results from other studies using the CNN
approach. Given that the AUC in the protein-ligand models was already high, adding the water channels
resulted in no detectable increase in the test set AUC.
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Figure 11. The performance of receptor-ligand and receptor-ligand-water CNN models.
10 targets were randomly picked from DUD-E database.
Performances of the receptor-ligand and ligand-only CNN models are equivalent
Given the high AUC achieved by receptor-ligand models, we were interested in whether these models have
successfully learned from the protein-ligand molecular interactions or were instead learning from ligand
bias. To test this, we built two single-target CNN models for each DUD-E target: the receptor-ligand model
and the ligand-only model. The receptor-ligand model was trained on the receptor-ligand 3D binding pose,
while in the ligand-only model, each receptor structure was replaced by a single identical dummy atom. The
model was therefore trained by the ligand binding pose alone without any meaningful receptor information.
Strikingly, as shown in Figure 12, the AUC values achieved by the receptor-ligand model and ligand-only
model were highly correlated (R2 = 0.98, slope K = 0.99). Both the receptor-ligand model and ligand-only
model achieved an average AUC of 0.98, with AUC greater than 0.9 for all 102 DUD-E targets. The average
absolute difference in the AUC values of the two types of models for the 102 targets was 0.001. This
suggests that the CNN algorithm can determine a set of parameters to accurately distinguish the actives
from the decoys for a specific target regardless of whether the receptor structure is provided or not.
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Figure 12. Correlation between the performance of the receptor-ligand and ligand-only CNN
models.
The receptor-ligand CNN model was trained on receptor-ligand 3D binding poses, and the ligand-only
CNN model was trained on ligand binding poses alone. Each blue dot is a target from DUD-E; There are
102 targets in total.

The receptor-ligand model does not learn from protein structure information
Given the ligand model’s high performance, we were interested in determining how much the receptor
structure contributed to the receptor-ligand model’s performance. To test this, we used the same receptorligand model trained as above on the receptor and ligand information and then tested it on two datasets.
The first dataset input all the appropriate structural information into the channels for both the receptor and
ligand. The second testing dataset used all the ligand structure information but replaced the receptor
structure information with information for a single dummy atom, thereby providing no protein structure
information. The results of these tests are shown in Figure 13. Surprisingly, the receptor-ligand models
performed almost exactly the same regardless of whether information on the receptor was provided in the
test set. The average AUC for both datasets is 0.98, and the average absolute AUC difference between the
two testing sets is 0.0006, with the largest difference (0.027) for FABP4. This strongly suggests that the
receptor-ligand model is learning almost entirely from the ligand information and not from receptor-ligand
binding patterns. It is generally thought that CNN algorithms will use all the information from the input to
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optimize the model parameters. Strikingly, here, we show that for almost all targets, only the ligand
information was necessary for the receptor-ligand model to distinguish the actives and decoys, meaning
information provided about the receptors and receptor-ligand binding patterns was not utilized.

Figure 13. Performance of the receptor-ligand model with and without receptor information.
For each target, red dots indicate performance when the receptor structure was provided in the test set,
while blue triangles indicate performance when the receptor structure was replaced by a single dummy
atom. The x-axis displays each DUD-E target in the same order as they appear in the DUD-E database
(http://dude.docking.org/targets). The targets with even indices are not labeled on the x-axis due to space
limitations.

To further investigate what the receptor-ligand CNN model had learned, we extracted the weights of the 32
filters (3*3*3*35 dimension) from the first convolutional layer of the trained AA2AR receptor-ligand CNN
model. As shown in Figure 14A, in the trained model, the weights placed on the receptor (atom type 0 to
atom type 15) are much smaller than those placed on the ligand (atom type 16 to atom type 34). Of note,
given that in the CNN model there were many layers through which values were transformed nonlinearly,
we also compared the ligand scores predicted by the AA2AR receptor-ligand model on the AA2AR ligands
with or without receptor information provided. As shown in Figure 14B, the predicted ligand scores were
highly correlated (R2 = 0.998) between the case when the receptor information was provided in the test set
and when it was not, which strongly suggested that the receptor-ligand CNN model did not utilize the

43

receptor information in making its predictions even though the receptor structure was provided during
training. Similarly, high correlation between ligand scores predicted by receptor-ligand CNN models with or
without receptor information provided in the test set was observed for all 102 DUD-E targets (Figure S1,
R2 = 0.988).

Figure 14. The weight and predicted ligand scores of AA2AR receptor-ligand CNN model.
(A) The average weight put on each atom type in the 32 filters from the first convolutional layer of the
AA2AR receptor-ligand CNN model; atom types 0-15 are from the receptor, and atom types 16-34 are from
the ligand. (B) Correlation between scores predicted by the AA2AR receptor-ligand CNN model on ligands
with vs. without receptor information provided. R2 = 0.998.

Performance of ligand fingerprint-based KNN models
The high AUC values achieved by the ligand-only CNN model indicated that, for each target, the actives
are easily distinguishable from the decoys. To test whether the actives could be distinguished from the
decoys using a fingerprint-based feature space, for each target, we calculated ligand fingerprints using the
RDKit python package with the default “RDKit” fingerprints in 2048 bits. These fingerprints were then used
to build ligand-KNN models where internal cross-validation was used to select the best K values. We then
tested these models using the same training and test sets as used for the ligand-trained CNN models. As
shown in Figure 15, for all 102 targets, the ligand-KNN models achieved AUC values greater than 0.82, 97
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of which were greater than 0.90. It is noteworthy that a simple KNN model performed only slightly worse
than a ligand CNN model. In addition, the AUC values from the ligand-only CNN models are moderately
correlated (Pearson correlation R = 0.59, average absolute difference 0.02). For example, AUC values that
were relatively lower compared to other targets in the KNN models were generally also relatively lower in
the CNN models. Further, 96 (94%) targets have a best K equal to 1 or 2, indicating that simple nearest
neighbor similarity is highly effective on most DUD-E targets (Table 2). The high performance achieved by
the KNN model indicates that, for each target, the actives and decoys are clustered into two separable
clusters in the fingerprint-based high dimensional feature space. As the atom type features are correlated
to the fingerprint features, the correlated performance between the ligand-based CNN model and KNN
model indicates that the high performances of the ligand-only CNN model are attributable to the high
similarity among the actives or decoys and distinct separation of these two groups from each other in the
feature space.

Figure 15. Performance of ligand-trained KNN and CNN models.
Each dot represents a target from DUD-E database as shown by X-axis
Table 2. The best-K value distribution for 102 ligand-trained KNN models
K value

Frequency

Percentage

K=1

79

77.45%

45

K=2

17

16.67%

K=3

4

3.92%

K=4

0

0.00%

K=5

2

1.96%

Total

102

100%

Intra-target analogue bias and decoy bias
The high AUC values achieved by the ligand-only CNN model indicated that the actives could be
differentiated from the decoys based on the ligand information alone. One possible explanation is that for
each target, the actives are analogous, which may lead them to cluster together in the high dimensional
space defined by the input representation (analogue bias). In addition, the decoy selection criteria may
result in decoys that are easily distinguishable from the actives even in absence of analogue bias (decoy
bias). To explore the effects of these biases, we examined the distribution of prediction scores calculated
by our ligand-trained CNN models for the actives and decoys. The AA2AR testing set, which had an AUC
of 0.98, is a representative example. As shown in Figure 16A, the scores of most actives were higher than
those of the decoys, and most of the actives had prediction scores clustered very closely 1, while the
majority of the decoys had scores clustered very closely around 0. This score clustering phenomenon was
observed for all 102 targets, with the average predicted score for all actives and decoys across all testing
sets being 0.90 ± 0.24 and 0.04 ± 0.15, respectively (Figure S2). Because only ligand information was used
to train these models, the highly clustered nature of the prediction scores for the actives and decoys around
1 and 0, respectively, suggests that the models are learning ligand features that allow them to separate
these two groups very well; these may include both analogue and decoy bias.

It is well-accepted that a large training set is required for CNNs to detect patterns and achieve reliable
performance. Here, to determine the degree of distinguishability between the actives and the decoys, for
each DUD-E target, we randomly selected five actives and five decoys from the previous training set to
train the ligand model and then tested the model on the same test set as before. In order to observe how
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the choice of ligands included in the training set affected the model’s performance, we repeated this
procedure three times using different actives and decoys to train the model each time. As shown in Figure
16B, although the training sets were extremely small, the ligand CNN model still achieved high AUC values
for many targets (Table S2), which suggests that the five actives and five decoys in the training sets were
able to adequately capture the landscapes of the remaining actives and decoys. The varied standard
deviations reflect different levels of analogue and decoy bias for each target. Targets with low standard
deviation are likely to have actives and decoys with highly distinguishable features that can be easily
extracted from an extremely limited training set, leading the model to successfully separate actives from
decoys.

Figure 16. Actives and decoys are generally distinguishable for DUD-E targets.
(A) The prediction score of actives and decoys in AA2AR as a representative example; (B) Performance
of ligand-trained CNN models trained on small sets of five actives and five decoys. The dots represent
mean values, and the bars represent standard deviation.

Inter-target prediction of ligand-trained CNN models
To test a model’s capacity for generalization, many groups have used sequence similarity filters to separate
DUD-E targets into diverse training and testing sets. However, this is based on the untested assumption
that targets in DUD-E with low sequence similarity have distinct actives. Here, to determine the presence
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of analogue and/or decoy bias across DUD-E targets, we ran each single-target ligand-trained CNN model
against the ligands from all other 101 targets. As shown in Figure 17A, high AUC values not only occurred
within targets (diagonal line) but also commonly occurred across targets (AUC values are in Table S3). For
74 targets, the actives and decoys were accurately distinguished (AUC> 0.9) by one or more models trained
on the ligands of other targets (Figure 18). We chose a high AUC value threshold here to ensure that the
effects were not due to statistical fluctuations or noise. As expected, models trained by targets within a
similar functional category, even those with very low protein sequence similarity, are likely to have high
inter-target AUC values. This indicates the sequence similarity threshold is not rigorous enough to exclude
bias when constructing training and test sets. For example, actives and decoys for TGFR1 (TGF-beta
receptor 1, index = 92) were accurately distinguished by 28 models trained by ligands from other targets
(Table S4). All of these 28 targets plus TGFR1 belong to the category of phosphate-related enzymes, and
24 of them, including TGFR1, are kinases. Of note, these comprise almost all of the 26 kinases present in
the DUD-E database. As shown in Table S5, very few ligands are active against multiple non-isoform
targets in the DUD-E. This excludes the possibility that such high inter-target AUC values resulted from
different targets having the same actives. This suggests that models trained on kinase targets might have
learned shared features of kinase substrates (analogue bias) that makes them perform well for kinase
targets in general. However, unexpectedly, high inter-target AUC values frequently occurred for targets that
had neither sequence similarity nor shared functionality. As an illustrative example in Table 3 shows that
11 models achieved high AUC (greater than 0.9) values for COMT despite the fact that none of the
corresponding targets share significantly similar protein sequence (30%) or functionality with COMT.
Inspired by the AVE bias matrix reported by Wallach et al.113, we calculated the four mean Fingerprint
(ECFP4)-based Tanimoto distances between the actives and decoys in the training sets with the actives
and decoys in the COMT testing set (training actives to COMT actives, training decoys to COMT actives,
training actives to COMT decoys, and training decoys to COMT decoys). We found that these four were
similar for all 11 targets and that they were all higher than 0.87 (Figure S3), which suggests that these high
inter-target AUC values do not result from analogue bias. Instead, the models have likely learned features
that allow actives and decoys to be easily distinguished (decoy bias).
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The decoy bias in DUD-E results from the criteria for selecting decoys. To remove the contribution of decoy
bias to the high inter-target AUC, we constructed the Actives as Decoys (AD) dataset and tested the ligand
models on this dataset. As shown in Figure 17B, the number of models yielding a high AUC for each target
is significantly decreased (AUC values of AD dataset are in Table S6, AUC histogram distribution of two
datasets is in Figure S4), which indicates that, for a specific target, models that are trained on the actives
of other targets cannot distinguish the actives of that target from the actives of other targets. The fact that
the ligand-only CNN model performs well on the default DUD-E dataset but poorly on the AD dataset
suggests that, for each target, the ligand-only CNN model learned the biased feature pattern of that target’s
decoys, and the model will perform well on other targets if their decoys fit the same biased feature pattern.
The decreased performance on AD datasets also occurred when using KNN models (Figure S5 and Figure
S6).

Figure 17. Inter-target prediction performance of ligand-only CNN models.
A) Ligand-only CNN model tested on test sets composed of actives and default decoys (B) Ligand-only
CNN model tested on test sets composed of actives and AD decoys. The target order is the same as in
DUD-E.
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Figure 18. Total number of inter-target models that achieved AUC>0.9 for each target in DUD-E.
Targets are partitioned into subsets based on biological families. Targets from a different subset (or nonisoform targets in the "other" subset) are labelled “distinct targets” (blue). Targets in the same subset
(except the “other” subset, unless an isoform exists) are labelled “similar targets” (orange). Targets that do
not have inter-target high AUC (>0.9) are not shown.

Table 3. Ligand-only CNN models that achieve AUC > 0.9 for COMT
Test set

COMT (Methyltransferase)

Model trained by

AUC

Sequence similarity*

ADA (Adenosine deaminase)

0.934

11/21

CASP3 (Caspase-3)

0.952

No Match

CP3A4(Cytochrome P450)

0.901

8/23

DEF (Peptide Deformylase)

0.950

No Match

GRIA2(Glutamate receptor)

0.926

No Match

HIVINT (HIV integrase)

0.998

3/8

HMDH (HMG-CoA reductase)

0.930

11/33

HS90A (Hot shock protein)
INHA (Mycobacterium tuberculosis
enoyl reductase)
PPARG (Peroxisome proliferatoractivated receptor)

0.994

5/14

0.964

8/32

0.951

15/54

THB (Thyroid hormone receptor)

0.910

No Match
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*From the NCBI BLASTp program using the default parameters. x/y is the sequence identity, where x is the
number of identical amino acids in the local alignment and y is the total number of amino acids in the local
alignment. “No Match” means no alignment was possible for the two sequences. All 11 targets are not
homologous to COMT based on a 30% sequence similarity threshold.

To distinguish intra-target analogue bias, inter-target analogue bias, and decoy bias in the performance of
the ligand-only CNN model, we categorized the 102 * 102 AUCs (Figure 17) into three groups: 1) A “same
target” group (red in Figure 19), in which the models used for prediction were trained and tested on the
same target; 2) A “similar function” group, in which the models used for prediction were trained on proteins
with a similar function as the test set. The functional groups for this were: kinases, proteases, GPCRs, and
nuclear receptors. (blue in Figure 19) 3) A “different function” group, in which the models used for prediction
were trained by targets with different functionality than the proteins in the test set (grey in Figure 19). Table
4 shows the average AUC for these three groups, and Figure 19 shows the AUC distribution for each group
for the both the DUD-E dataset and to the AD dataset.

The AUC values for the “same target group” were the highest on average for both the DUD-E and AD
datasets. We attribute this high performance regardless of dataset to intra-target analogue bias which is
consistent with the conventional wisdom that ligands that bind to the same target have chemical similarities.
Similar results are seen in the blue curves which we attribute to inter-target analogue bias which is
consistent with general belief that compounds that bind to proteins with similar function often have similar
chemical features. As expected, the inter-target analogue bias is less than the intra-target analogue bias.

The average AUC values for all three groups are lower for the AD dataset than for the DUD-E dataset
(Table 4 and Figure S7). We attribute these differences to the contribution of decoy bias to the model
performance as the AD dataset was designed to eliminate the decoy bias that was introduced by the DUDE decoy selection criteria. In this work, we proposed that the CNN models could learn from three different
sources: 1) protein-ligand interaction 2) analogue bias and 3) decoy bias. Since the receptor information is
absent from the ligand-only model, it could not learn from the first source. The analogue bias and decoy
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bias were controlled for in the “different function” group in the AD dataset, we therefore expect that the
model would perform randomly on this group, and, indeed, the average AUC for the “different function”
group in AD dataset was 0.500.

Figure 19. AUC distribution for the ligand-only CNN model across three groups of targets.
(A) Results for models tested using the DUD-E dataset; (B) Results for models tested using the AD dataset.
The distributions are normalized such that the area under each distribution curve equals 1.

Table 4. The mean and SD of the AUC values across three target groups

DUD-E
dataset
AD dataset

Same Target

Similar Function

Different Function

Mean

0.983

0.835

0.618

SD

0.019

0.133

0.176

Mean

0.927

0.682

0.500

SD

0.060

0.137

0.165

Multi-target CNN model
To investigate whether a CNN model trained on a subset of targets could be applied successfully to a new
target, we trained the receptor-ligand and ligand-only CNN models on a training set of ten targets (AA2AR,
CXCR4, FA10, FABP4, GLCM, HIVPR, ITAL, KIT, KITH and LCK) and then applied these two models to
the remaining 92 DUD-E targets. As shown in Figure 20, the receptor-ligand and ligand-only CNN model
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showed similar performance (both with AUC 0.80 ± 0.13) when tested on the remaining 92 targets. To
investigate whether the receptor information was utilized by the receptor-ligand model when trained by
multiple targets, we also applied the model to a testing set wherein the receptor was replaced by a dummy
atom. As shown in Figure S8, the receptor information was not utilized in most cases. We also tested the
multi-target-trained ligand-only model and receptor-ligand model on AD datasets. As shown in Figure S9
and Figure S10, the AUCs shifted downward for all targets, and the average performance was similar to
that of random chance.

Figure 20. Performances of multi-target trained receptor-ligand and ligand-only CNN model.
The two models were trained on 10 targets and tested on the remaining 92 targets. The receptor-ligand
CNN model was trained on receptor-ligand 3D binding poses, and the ligand-only mode was trained on
ligand binding poses alone. Each black dot represents a target.

Performance of CNN models trained on the PDBbind database
Apart from categorical prediction, many recent studies102,103,107,116,122 have also showed that deep learning
models trained on the PDBbind123 “refined” set can predict binding affinity in the “core” set to a Pearson
correlation coefficient of ~0.8 or root-mean square deviation (RMSD) < 2 in terms of pKi or pKd. However,
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as Yang et al.

124

showed, sequence similarity has a significant effect on the performance of machine

learning-based scoring functions. Therefore, the fact that the core set overlaps with the refined set even
when the core set items are removed from the refined set could make the reported performance overoptimistic. Here, we tested two previously-trained open-source structure-based CNN models, the Gnina
model116 and the Pafnucy model103, on all 102 DUD-E targets and compared their performance with that of
Vina. Briefly, the Gnina model was trained by Hochuli et al.116 on docked poses from the PDBbind refined
set; poses that were within 2 Å RMSD of the crystal structure were assigned the same binding affinity as
the crystal pose, while poses that had RMSD values greater than 4 Å from the crystal structure were trained
using a hinge loss that only penalized over-prediction of the associated affinity. In contrast, the Pafnucy
model was trained by Dziubinska et al. 103 on a “filtered refined set” of protein-ligand crystal structure data
constructed by removing the core set from the PDBbind refined set. Since the Pafnucy model was trained
on protein-ligand crystal structures that the ligands in DUD-E do not have, we fed both models with the top
nine docked poses, as studies85,125 have shown that the probability that a successful pose RMSD (< 2 Å)
is present within the top three poses is high (~80%). In each case, the top ranked pose was used to score
a given ligand. As shown in Figure 21, the performance of these three models varies from target to target.
As summarized in Table 5, Vina performed comparably to Gnina, and they both performed better than
Pafnucy.

Figure 21. The AUC value distribution for Vina, Gnina and Pafnucy performed on DUD-E.
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Each black dot represents a DUD-E target.

Table 5. Summary of Vina, Gnina and Pafnucy performance on DUD-E

Vina
Gnina
Pafnucy

Average AUC
0.725
0.709
0.632

Frequency (AUC>0.8)
24
28
12

Frequency (AUC>0.9)
3
10
0

Pose sensitivity
It is generally thought that models that can learn protein-ligand binding patterns will gain the ability to
generalize which can, in turn, lead to good prediction of actives for a wide range of targets. However, our
results have shown that good prediction in a test set does not necessarily mean the model has learned
physical binding patterns. To further investigate whether the open-source structure-based CNN models
have learned meaningful features from binding patterns, we tested Gnina and Pafnucy’s performance on
Human blood coagulation Factor Xa (FXa). FXa is a drug target for anti-coagulation therapy and a series
of compounds with different levels of binding affinity have been synthesized, which provides a dataset to
assess the scoring function’s sensitivity to ligand chemical components126,127. Among these compounds,
XLC (PDB ID: 1MQ5) and XLD (PDB ID: 1MQ6) are two chemically-similar ligands with high-quality crystal
structures, and their binding affinities were determined to 1 nM for XLC and 7 pM for XLD, respectively128.
To evaluate the pose sensitivities of Gnina and Pafnucy, we re-docked each ligand to the binding pocket
to generate 100 different poses with root mean squared distance (RMSD) of heavy atoms ranging from
0.0–6.0 Å. As shown in Figure 22, for Vina and Gnina, although the chemical components of the ligands
are same, different binding affinities were predicted. In contrast, for Pafnucy, except for the fact that the
crystal poses were predicted to have a different binding strength, all other poses were predicted to have
nearly identical affinity even when the RMSD was large. This may be because the Gnina model was trained
by sets of docked poses for each ligand, among which “crystal-like” poses were assigned good affinity while
poses less similar to the crystal-like pose were assigned lower affinity. On the other hand, the Pafnucy

55

model was trained only by crystal poses, which may lead the model to be insensitive to pose change. All
three methods all failed to distinguish the affinity difference between XLC and XLD, indicating accurate
binding affinity prediction for similar ligands remains a challenge.

Figure 22. Pose sensitivity of Vina, Gnina and Pafnucy.
The three models were tested on 100 re-docked poses of ligand XLC (A) and ligand XLD (B). The red
asterisk at the RMSD=0 marks the experimental affinity. Vina predicts free binding energy (ΔG) in kcal/mol;
here, we estimated the Ki at 25 Celsius using the equation ΔG=RTlnKi, where R is the gas constant (8.31
J/K·mol).

2.4.6 Conclusions
In this study, we showed that the performance of protein-ligand CNN models is affected by hidden biases
in the DUD-E dataset. We showed that analogue biases are common both within the sets of actives
associated with each target (intra-target analogue bias) and across sets of actives associated with different
targets (inter-target analogue biases). We further provided evidence for the existence of decoy bias likely
resulting from the selection criteria used during construction of the DUD-E dataset. Analogue bias and
decoy bias allow CNN models to learn entirely from the ligands even though protein structure information
for the target is provided during the training stage. We also tested additional CNN models trained by proteinligand crystal structure data from PDBbind. Although these models were reported to have good
performance in their test datasets, they did not outperform the docking program Autodock Vina on average
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when tested using DUD-E. Our studies suggest that 1) DUD-E should be used with extreme caution when
applied to machine learning-based method development and ideally should be avoided and 2) rigorous
testing of a model’s response to different types of information in training/test sets is essential to building a
meaningful model.

2.4.7 Discussion
As deep learning methodologies have been increasingly applied to virtual screening, our study suggests
that caution should be taken as hidden bias may exist in datasets used to develop these methods. We have
shown evidence for both analogue and decoy bias in the DUD-E dataset. Analogue bias most likely
originates from the fact that ligands binding to a specific target (or to a set of targets with similar functionality)
are likely to have similar scaffolds, resulting in similar topological features that are easily captured by CNN
architectures. Decoy bias in DUD-E was introduced by the criteria that were used to select the decoys for
each target. For example, in DUD-E, to control the false decoy rate, for each active, candidate decoy
compounds were sorted by the topological fingerprint-based Tanimoto Correlation, and the top 75% were
removed, leaving only the 25% most dissimilar compounds as decoys for that active110. Although these
criteria minimize the false decoy rate, they also cause the decoys to be easily distinguishable from the
actives by machine learning models. Also, Sieg et al. 129recently published an analysis of the molecular and
physical properties of the actives and decoys from DUD-E, which showed that certain properties are
exclusive to one group or the other. For example, compounds with molecular weight greater than 500 Da
include actives only. They also suggested these simple distinguishable features between actives and
decoys allow machine learning-based models to distinguish DUD-E actives from decoys on the basis of the
ligands themselves, which is consistent to our findings. Together, the biased basic properties of the ligands
and overly conservative selection criteria may also result in overall separation of the decoys and actives in
the high-dimensional space constructed by the combination of all their features such that models can
distinguish the non-binders from binders in general but cannot tell which target each binder associates with.
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Besides bias, there are many additional obstacles that lie on the road to successfully applying deep learning
to virtual screening. One is data quality. In the image recognition domain, humans can easily recognize
images in any number of different contexts; for example, we perceive automatically that two pictures of a
cat in which the cat’s tail has shifted positions are still both of a cat. As a result, humans can provide vast
amounts of high-quality data to train image recognition models. Unfortunately, without expert knowledge,
we do not know whether a small shift of a chemical group will affect a compound’s ability to bind to a target
with the same level of affinity. This introduces uncertainty into the quality of pose data that is fed into binding
prediction models when docked poses are used as training input. Another challenge is data paucity. Current
deep learning models can easily have more than 30 atom type channels, significantly more than image
recognition models, which only have three channels. The increased dimensionality exacerbates the paucity
of protein-ligand crystal structure information, and the millions of parameters-much more than the current
number of available data points-encourages the model to simply memorize the entire set of data points,
complicating generalization to novel compounds. In summary, low data quality and data paucity together
make it a very challenging task to develop a deep learning model for binding affinity prediction that can
generalize to new protein targets and different ligand scaffolds. Here, we also showed that high
performance in test sets is not enough to make the model generally applicable, as hidden biases may exist
in the training/testing datasets that can lead the model astray. To ensure that models have learned
meaningful features, we should test them by interrogating their response to different types of training or
testing information and ensuring their sensitivity to ligand binding pose.

In this work we have introduced controls in datasets to test whether a model is learning from protein-ligand
interactions, analogue bias or decoy bias. By removing receptor information from the test set for receptorligand models, we can determine how much the model is learning from the receptor and hence from proteinligand interactions. Similarly, testing on a dataset that does not share decoy bias introduced by the decoy
selection criteria (as we did with the AD dataset) helps identify how much a model is learning from decoy
bias. Inter-target validation on test sets from which proteins that share homology and functional similarity
with training set proteins have been removed controls for real analogue bias and constructed decoy bias.
These tests should be expanded upon and refined in the future and be broadly applied to machine learning
outcomes to ensure that the machine learning black box is learning from meaningful information that is
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generalizable to making prospective predictions on molecular recognition. In this study, we highlighted the
danger of attributing a model’s high performance in a test set to successful generalization of binding
interactions without rigorously validating the model. Although many machine learning-based methods have
been developed and tested on DUD-E, we clearly showed here that analogue bias and decoy bias are
widespread in DUD-E and, consequently, models may only learn the inherent bias in the dataset rather
than physically meaningful features. We hope this work can help our community become more aware of
the pitfalls of current databases and develop more robust and meaningful deep learning models for drug
discovery.

2.4.8 Supporting information

Figure S1. Correlation of ligand scores by receptor-ligand CNN model with vs. without receptor.

We compared the scores output by the receptor-ligand CNN model when it predicts on a test set with vs.
without receptor information provided. For most of the test sets, provision of receptor information does not
affect the receptor-ligand CNN model’s output scores.

59

Figure S2. The distribution of predicted scores of all actives and decoys in DUD-E.

The predicted scores are clustered around 1 or 0, which suggests actives and decoys are easily
distinguished by the CNN models.

Figure S 3. The average Tanimoto distance to COMT test set.
The average fingerprint-based Tanimoto distance between the actives and decoys from training sets and
COMT test set. The ligand-only models trained by these 11 targets all achieved high AUC in COMT.
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Figure S4. AUC distribution for DUDE and AD dataset.
The distribution of AUC values achieved by ligand-only CNN models tested on the default DUD-E dataset
and the AD dataset. In the default dataset, the decoys are the DUD-E decoys, while in the AD dataset, the
AD decoys are the actives from other targets.

Figure S5. Performance of KNN model on DUDE and AD dataset.
Replacing the default DUD-E decoys with AD decoys removes decoys biases; hence, the KNN model
performs worse on the AD dataset than the default DUD-E dataset.
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Figure S6. The distribution of AUC achieved by KNN model.
The distribution of AUC values achieved by the KNN model tested on the default DUD-E dataset and the
AD dataset. The left shift of the AUC values achieved by the KNN model for the AD dataset suggested that
KNN model partially learned from the biases in the DUD-E decoy dataset.

Figure S7. The distribution of AUC in three groups.
The distribution of AUC values in each target group using DUD-E and AD dataset. The left shift of the AUC
values for the AD dataset suggests that model learned the biases in DUD-E decoy dataset.
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Figure S8. Performance of receptor-ligand model with or without receptor provided.
Performance of the receptor-ligand model for the same ligand test sets with and without receptor
information. For each target, red dots indicate performance when the receptor structure was provided in
the test set, while blue triangles indicate performance when the receptor structure was replaced by a single
dummy atom.

Figure S9. Multi-target ligand model tested on DUD-E and AD dataset.
Multi-target trained ligand-only models tested on 92 targets with default decoys and AD decoys. The
average AUCs of the default and AD testing sets are 0.80 and 0.53, respectively.
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Figure S10. Multi-target receptor-ligand model tested on DUD-E and AD dataset.
Multi-target trained receptor-ligand model tested on 92 targets with default decoys and AD decoys. The
average AUCs of the default and AD testing sets are 0.80 and 0.54, respectively.

Table S1. Atom types used in our CNN model. There are 35 atom types (channels) in total: the first 16
channels are from the receptor, and the remaining 19 channels are from the ligand.

Receptor Atom Types

Ligand Atom Types

AliphaticCarbonXSHydrophobe

AliphaticCarbonXSHydrophobe

AliphaticCarbonXSNonHydrophobe

AliphaticCarbonXSNonHydrophobe

AromaticCarbonXSHydrophobe

AromaticCarbonXSHydrophobe

AromaticCarbonXSNonHydrophobe

AromaticCarbonXSNonHydrophobe

Calcium

Bromine

Iron

Chlorine

Magnesium

Fluorine

Nitrogen

Nitrogen

NitrogenXSAcceptor

NitrogenXSAcceptor

NitrogenXSDonor

NitrogenXSDonor

NitrogenXSDonorAcceptor

NitrogenXSDonorAcceptor

OxygenXSAcceptor

Oxygen

OxygenXSDonorAcceptor

OxygenXSAcceptor

Phosphorus

OxygenXSDonorAcceptor

Sulfur

Phosphorus

Zinc

Sulfur
SulfurAcceptor

64

Iodine
Boron

Table S2. AUC values achieved by the ligand-only CNN models trained by a small number of
actives/decoys for each target (Included in Supporting Materials).
Replication n = 3.

Table S3. AUC values for the 102*102 cross-target prediction by ligand-only CNN models tested on
the DUD-E dataset (Included in Supporting Materials).

Table S4. The ligand-only CNN models that achieved high AUC for TGRF1 and the functionality of
the targets that the models were trained on.
Per-target ligand Model

Funtion Category

aa2ar

GPCR

abl1

Kinase (Tyrosine)

akt1

Kinase

akt2

Kinase

braf

Kinase

cdk2

Kinase

csf1r

Kinase

cxcr4

GPCR

egfr

Kinase

fak1

Kinase

fgfr1

Kinase

hxk4

Kinase

igf1r

Kinase

jak2

Kinase

kith

Kinase

kpcb

Kinase

lck

Kinase

mapk2

Kinase

met

Kinase
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mk10

Kinase

mk14

Kinase

mp2k1

Kinase

parp1

Polymerase

pde5a

Phosphodiesterase

pnph

Purine nucleoside Phosphorylase

rock1

Kinase

src

Kinase

vgfr2

Kinase

Table S5. Active overlap among the 102 DUD-E targets (Included in Supporting Materials).

Table S6. AUC values for the 102*102 cross-target prediction by ligand-only CNN models tested on
the AD dataset (Included in Supporting Materials).
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Chapter Three: Solvation Free Energy Calculation by Grid
Inhomogeneous Solvation Theory
3.1 Grid Inhomogeneous Solvation Theory
GIST is a 3D discretization of the inhomogeneous solvation theory (IST)130, in which the solute is considered
to be rigid at the origin and generates an external field that creates solvent density fluctuations around it.
In IST, energy is broken down into solute-water energy and water-water energy (eq. 14):

Eq. 14

E = ρ 0 ∫ gsw (r)[Esw (r) + Eww (r)]d r
where

ρ0

(1)

is the number density of bulk water,

position r, and

Esw (r) and Eww (r)

gsw (r)

is the solute-water pair-correlation function at

are the solute-water interaction energy and the change of water-water

interaction energy at position r, respectively.

IST breaks down non-ideal (or excess) entropy of an inhomogeneous system into a first order term, a
second order term, and high order terms (eq. 15):
Eq. 15

S = S 1 + S 2 + ...
The first order entropy term accounts for the solute itself, the second order entropy term accounts for the
solute-water correlation entropy, and the high order energy terms account for many-body correlations, for
example, solute-water-water correlations. IST has inspired the development of many novel computational
tools to analyze thermodynamics and obtain insights into highly occupied water sites using molecular
dynamics simulation. Pioneering tools include WaterMap131 and Solvation Thermodynamics of Ordered
Water (STOW)132.
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In GIST, the thermodynamic and structural properties of water molecules are assigned to the voxel
occupied by the oxygen atom of the water, resulting in discretization of the integrals of IST onto 3D grid
maps. GIST has many advantages in mapping the water thermodynamics. First, rather than just measuring
the thermodynamics of the water molecules in the highly occupied sites, GIST measures the properties of
all water molecules in a defined three-dimensional grid. If the grid covers the entire system, then GIST can
provide a framework for end-state free energy analysis, which hydration site analysis cannot do. Second,
GIST breaks down the non-bond interactions into water-solute interactions and water-water interactions,
thus providing more insights into the solvation process. Third, GIST implemented a near neighbor algorithm
for entropy calculation, allowing for better convergence than classical histogram methods.

3.2 Thermodynamic Integration
The free energy difference between state X and state Y is considered to be one of the most important
quantities in thermodynamics. For example, the binding free energy of a ligand to a protein target is the
free energy difference between the unbound state X where the ligand is solvated in water while far away
from the protein and the bound state Y where the ligand is bound to the protein, and the solvation free
energy of a small molecule is the free energy difference between the state X where the molecule is solvated
in water and the state Y where the molecule is in a vacuum (Figure 23). These two quantities are both
paramount to drug discovery. There are many theoretically rigorous approaches to calculating free energy
differences. Here, I will focus on TI, which we used in the study that comprises the second part of this thesis.
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(A) Protein-ligand binding

(B) Ligand solvation

Figure 23. The initial and end state in protein-ligand binding (A) and ligand solvation (B).

The Helmholtz free energy A of a system with constant pressure, volume, and temperature (NVT ensemble)
can be written as (eq. 16)
Eq. 16

A = −k BT lnQ
where

kB

is the Boltzmann constant and Q is the partition function of the system. In TI, a coupling

parameter λ is used describe the Helmholtz free energy A( λ ) of an alchemical intermediate state between
state X and state Y. Typically, a linear combination is used (eq. 17):
Eq. 17
A( λ ) = λ A( X ) + (1− λ ) A(Y )

The Helmholtz free energy difference between state X and state Y can be calculated as eq. 18:
Eq. 18
1

1

∂ A( λ )
∂Η( λ )
dλ = ∫ 〈
〉λ d λ
∂
λ
∂
λ
0
0

ΔA = ∫
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where Η( λ ) is the Hamiltonian function of the alchemical intermediate states. In practice, the equilibrium
states at a set of discrete λ values are simulated, and 〈

∂Η( λ )
〉 is then determined at each λ .
∂λ λ

3.3 Implementation of PME-GIST and its application to solvation free energy
calculation

3.3.1 Significance

Although the formalisms of calculating energy and entropy in IST are exact, the energy and entropy
calculations in initial implementation of GIST (GIST-2016) have two limitations117. First, non-bond
interactions were calculated using a minimum image convention algorithm, meaning that long-range
interactions were neglected. Second, only the solute-water entropy term was calculated, while the high
order entropy terms were truncated due to the untraceable sampling requirement. Here, I present our work
to implement PME-GIST in order to fully account for long-range interaction energies within the GIST
framework. With PME, the energy calculation in GIST is sped up to N log N from N 2 . We also suggest
a simple estimate for high order entropy terms. Our results show that by incorporating PME-based energy
calculations and the simple estimate for high order entropy, GIST can be applied to solvation free energy
calculation and achieve good agreement with reference methods such as TI.

3.3.2 Abstract

GIST maps out solvation thermodynamic properties on a fine meshed grid and provides a statistical
mechanical formalism for thermodynamic end-state calculations. However, differences in how long-range
non-bonded interactions are calculated in molecular dynamics engines and in the current implementation
of GIST have prevented precise comparisons between free energies estimated using GIST and those from
other free energy methods such as TI. Here, we address this by presenting PME-GIST, a formalism by
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which PME-based electrostatic energies and long-range Lennard-Jones (LJ) energies are decomposed
and assigned to individual atoms and the corresponding voxels they occupy in a manner consistent with
the GIST approach. PME-GIST yields potential energy calculations that are precisely consistent with
modern simulation engines and performs these calculations at a dramatically faster speed than prior
implementations. Here, we apply PME-GIST end-states analyses to 32 small molecules whose solvation
free energies are close to evenly distributed from 2 kcal/mol to -17 kcal/mol and obtain solvation energies
consistent with TI calculations (R2 = 0.99, mean unsigned difference 0.8 kcal/mol). We also estimate the
entropy contribution from the 2nd and higher order entropy terms that are truncated in GIST by the
differences between entropies calculated in TI and GIST. With a simple correction for the high order entropy
terms, PME-GIST obtains solvation free energies that are highly consistent with TI calculations (R2 = 0.99,
mean unsigned difference = 0.4 kcal/mol) and experimental results (R2 = 0.88, mean unsigned difference =
1.4 kcal/mol). The precision of PME-GIST also enables us to show that the solvation free energy of small
hydrophobic and hydrophilic molecules can be largely understood based on perturbations of the solvent in
a region extending a few solvation shells from the solute. We have integrated PME-GIST into the opensource molecular dynamics analysis software CPPTRAJ.

3.3.3 Introduction
IST133–139 provides a statistical mechanical framework to calculate the thermodynamics of solvation from
solvent molecular density distributions. Building upon IST, we developed WaterMap140 and GIST141,142 to
map out local water properties in high density spherical hydration sites and on a high resolution spacefilling grid, respectively, while others have developed their own methods of applying IST143–145. A major
motivation for the development of the grid-based implementation of IST, GIST, was the ability to account
for all water molecules in the system being studied as opposed to just the portion that occupied high density
regions as in WaterMap. In GIST, similar to an integration of hydrodynamic densities, a sum of density
quantities over all the voxels of the system yields the corresponding system quantities. As GIST accounts
for all the water in the system as well as the energetics of interaction between a solute and the water, sums
over voxel quantities in the initial and final states can be used to calculate corresponding differences in
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thermodynamic state quantities such as energies and entropies for rigid solute systems. Indeed, a couple
of studies145–147 have used IST to estimate free energies of solvation for small molecules and amino acids.
However, discrepancies between how GIST tools estimate energies and how molecular dynamics (MD)
engines calculate, particularly differences in the treatment of long-range interactions, have prevented
precise comparison between GIST-calculated energies and the energies produced from MD free energy
methods such as TI and FEP. Here, we address this by presenting a formalism by which PME-based
electrostatic energies148,149 and long-range LJ energies150 are decomposed and assigned to individual
atoms and the corresponding voxels they occupy in a manner consistent with the GIST formulation. This
PME-GIST approach yields electrostatic and LJ energy calculations that are consistent with the modern
simulation engine Amber-PMEMD151,152 at a dramatically faster speed than GIST without PME. In addition,
PME-GIST provides a more accurate solvation energy,

which, when combined with accurate

approximations of the entropy contribution from high order entropy terms, leads to improved agreement in
the solvation free energy compared with both TI and experimental measurements.

Here, we have run PME-GIST end states and TI calculations for the solvation free energies of 32 small
molecules chosen from the FreeSolv dataset153. These small molecules range from hydrophobic to
hydrophilic and have solvation free energies near evenly distributed over a range of 20 kcal/mol. For each
solute, we run simulations at three different temperatures to extract the solvation entropies from the
temperature dependence of the calculated free energies. Comparisons of these solvation entropies to
those calculated using IST leads to a simple linear scaling correction to the IST entropies. While the IST
formulation for system energies and entropies is formally exact, in practice, the N-body expansion for the
entropy is truncated after the first order term for inhomogeneous systems. Most IST implementations,
including the implementation of GIST154 in the MD analysis software CPPTRAJ155, account only for the
solute-water correlation entropy while neglecting the entropic contributions from correlations of two or more
water molecules. Exceptions to this include explicit calculation of higher order correlations though these
are not usually applied156–158. The differences between entropies calculated in TI and GIST are direct
estimates of the higher order entropy terms that are not calculated in GIST.
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Although the solvation energies calculated in the previous version of GIST implemented in CPPTRAJ
(GIST-2016) are highly correlated with TI, we find that PME-GIST significantly improves the agreement.
The 1st order entropies in PME-GIST are also highly correlated with the solvation entropies calculated in TI
(R2=0.92). Interestingly, while the energies and entropies of PME-GIST are highly correlated with TI, the
free energy is less so (R2=0.75) however corrections to the IST entropy to account for the missing higher
order terms leads to exceptionally high correlation between IST calculated free energies and TI (R2=0.99).
This leads us to conclude that in order to accurately calculate free energies with IST, the contribution of
higher order terms must be taken into account.

We further investigate whether the solvation free energy of these small molecules can be well described by
perturbations of the fluid proximal to the solute. We find that this is, indeed, the case for the full set of
hydrophobic and hydrophilic molecules investigated in this study and that integrating out to approximately
10 Å is sufficient to highly correlate with the total solvation free energy.

Our results suggest that including both the long-range interactions and the entropic contributions of higher
order water configurational correlations enables the use of GIST as a robust tool to measure solvation free
energy and its components both systematically and locally.

3.3.4 Methods
MD simulations
The 3D structures of the 32 neutral small molecules were obtained from the PubChem database159. The
atomic partial charges of the molecules were assigned using AM1-BCC in Antechamber160 and other
forcefield parameters were parameterized by the GAFF2 force field161. The solutes were then solvated in a
TIP3P162 rectangular water box, where the box’s edges are at least 15 Å from the solutes using tleap from
AmberTool20152 such that the solvated systems have between 1191 and 2004 water molecules. The system
was minimized and then heated to 300 K in 20 ps under NVT conditions using Langevin temperature control
with a time constant of 2 ps for the heat bath coupling163,164. The systems were then equilibrated for 250 ps
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at a constant temperature of 300 K and pressure of 1 bar maintained by the isotropic position scaling
barostat with a collision rate of 2 ps165. The MD simulations were performed using GPU-accelerated
PMEMD166,167 from Amber20 with periodic boundary. Electrostatic interactions were modeled by PME with
9 Å direct space cutoff. LJ interactions were fully accounted for up to a 9 Å cutoff and long-range interactions
were treated by the default isotropic long-range correction. The NPT production MD simulations were
conducted for 100 ns with a time step of 2 fs. System configurations were saved every 1000 steps for
subsequent GIST analysis. All solute atoms were harmonically restrained to the initial positions and at the
center of the systems by a 100 kcal/mol/Å2 force constant throughout all simulation steps. The lengths of
bonds involving hydrogen were constrained by the SHAKE algorithm168 after minimization steps.

TI calculations
The solvation free energy is calculated by Amber TI32,169 as:
Eq. 19
l =1

DGsolv = -

ò
l

=0

¶H
dl
¶l

where l=0 represents the solvated state in which the solute fully interacts with the surrounding water
molecules and l=1 represents the state in which the solute is decoupled from the solvent. For the TI
simulations, the systems were minimized, heated and equilibrated using the same protocol as for PMEGIST simulations except an additional 250 ps NPT equilibrium simulation performed before the 2 ns
production run for every λ. The TI calculations were conducted over 15 λ states (0, 0.05, 0.1, 0.15, 0.2, 0.3,
0.4, 0.5, 0.6, 0.7, 0.8, 0.85, 0.90, 0.95, 1.0) with a soft-core potential function using a one-step
transformation with parameters of αLJ=0.5 and βC=12170. TI simulations were run for each solute at three
different temperatures (270 K, 300 K, and 330 K) with three runs at each temperature for which the velocities
were randomly assigned prior to each 250ps equilibration. Solvation entropies were then estimated using
the finite-difference method171,172, in which the entropies were approximated by the slopes of solvation free
energies over temperatures.

74

GIST calculations
Both GIST-2016 and PME-GIST are implemented in CPPTRAJ. The GIST-2016 and PME-GIST
calculations were performed on 100 ns production trajectories with frames stored every 2 ps for a total of
50,000 frames for each trajectory. Cubic GIST grids that covered the entire systems with a resolution of
0.125 Å3 for each voxel were centered on the solutes with a bulk water number density of 0.03288 mol/Å3.
In the PME-GIST, the PME-based electrostatic energy calculation and long-range LJ correction were turned
on and a cutoff of 9 Å was used for both the direct space electrostatic interactions and short-range LJ
interactions. For each solute, GIST calculations were performed on three independent MD replicates.

In the output of the GIST calculations (GIST-2016 and PME-GIST), the energy density, entropy density and
water density are printed for each voxel. The total energy, entropy and water number of the system then
can be yielded by summing those densities multiplied by the voxel volume over the system (eq. 20-22). For
the total properties of a local region within a certain radius to the solute, GISTPP tool173 was used to define
the voxels belonging to that region and summing over the energy density, entropy density and water density
multiplied by the voxel volume over those voxels will yield the total energy, total entropy and total water
number for that region, respectively.
Eq. 20

Etotal = ∑ EdensVk
k

Eq. 21

Stotal = ∑ S densVk
k

Eq. 22

N total = ∑ ρ densVk
k

For the entropy calculations, voxels that were not entirely in the simulation box for the duration of the
simulation were removed from the sum in eq. 22. This occurs because the volume of the box fluctuates at
constant pressure. As the water in this region is distal from the solute, its properties are bulk like and the
contribution to the solvation entropy is zero.
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We also implemented a systematic correction to the GIST first order entropy calculation that accounts for
the systematic bias in the nearest neighbor algorithm174–176 that estimates this term. The first order entropy
term for a neat fluid should be zero; however, the nearest neighbor algorithm will yield a value for this term
slightly greater than zero due to limited simulation length147. To account for this systematic bias, we ran
TIP3P bulk water simulations in the same NPT condition and for the same duration as for other solute
systems. Conducting GIST calculations on the neat water simulations yielded a systematic bias of 0.00334
± 0.00003 kcal/mol per water in the first order entropy term for the TIP3P water model.

End-state calculation by GIST
In the end states calculation, the solvation free energy for a rigid solute was estimated by the difference in
free energy between a final state, in which a rigid solute fully interacts with the solvent; and an initial state,
in the rigid solute is fully decoupled from the solvent (eq. 23-25).
Eq. 23

DAsolv = DEsolv - T DSsolv
Eq. 24

ΔEsolv = E final − Einitial ′
Eq. 25

ΔSsolv = S final − Sinitial
Where DAsolv is the difference in the Helmholtz free energy between the two states, DEsolv and TDSsolv are the
difference in energy and temperature times the entropy difference of two states, respectively. The prime in
eq. 6 denotes the inclusion of a solute self-energy term in the initial state of the PME-GIST based solvation
energy calculation. This term includes non-bond interactions within the solute and between the solute and
all of its periodic replicas and is calculated by the energy command in CPPTRAJ. The energies per neat
water molecule (-9.5353 ± 0.0002 kcal/mol and -9.5422 ± 0.0002 kcal/mol) are calculated by running GIST2016 and PME-GIST, respectively, on 100 ns bulk water simulations in the same NPT condition as the
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solute-water simulations. The entropy calculations in GIST-2016 and PME-GIST are identical. In this study,
we use DEsolv to estimate solvation enthalpy and DAsolv to estimate solvation Gibbs free energy as the PDV
terms make negligible contributions to these systems.

3.3.5 Results
Modifications to the energy calculation in GIST
The total energy of the central unit cell in a periodic system is a sum the electrostatic energy and LJ energy
(eq. 26).
Eq. 26

Etotal = Eelec + Elj
Where the electrostatic energy of the cell can be written as (eq. 27):
Eq. 27

Eelec =

N N'
qi q j
1
ke
∑
∑
∑
2 n i j
| rj − ri + n |

And the LJ energy for the system is (eq. 28):
Eq. 28
N

N'

Elj = ∑ ∑ ∑
n

i

j

A(i, j )
| rj − ri + n |

12

−

B(i, j )
| rj − ri + n |6

in which qi and qj are the atomic partial charges of two atoms at position ri and rj respectively. N is the total
particle number in the unit cell, ke is the coulomb constant. A(i,j) (4esij12) and B(i,j) (4esij6) are the LJ parameters
of two atoms. n represents a vector between an atom in the unit cell and its image in a periodic cell. The
sum over n is over the full set of vectors that move a particle from the unit cell to each of its periodic images.
The prime on the second N (in eq. 27 and eq.28) indicates that in the unit cell, j is not within 1-4 interactions
of i.

In GIST-2016, both the electrostatic and LJ energies include only the interactions between pairs of particles
with the shortest distance (using the minimum image convention). In this study, we modify the way in which
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the energies are calculated by using PME-based electrostatic energy calculations and long-range LJ
corrections that account for all long-range interactions including the interactions between the particles in
the central unit cell and all periodic images of those particles.

Electrostatic energy calculation
In GIST-2016, the electrostatic energy of the unit cell is estimated by (eq. 29)
Eq. 29

Eelec !

qi q j
1 N N'
ke
∑
∑
2 i j
| ri − rj |*

The asterisk indicates the distance between two atoms is calculated by minimum image convention;
therefore, the electrostatic interactions longer than half the length of the unit cell’s diagonal are not included
in electrostatic energy in GIST-2016.

In PME, the total electrostatic energy (eq. 30) of the unit cell is broken down into a direct term, a reciprocal
term, and a correction term (eq. 31-33148,149).
Eq. 30

Eelec = Edir + Erec + Ecorr
Eq. 31

Edir =

N N ' q q erfc( β | r − r + n |)
1
j
i
ke ∑ ∑ ∑ i j
2 n i j
| rj − ri + n |

Eq. 32

Erec =

1 N
∑ q ψ (r )
2 i i rec i

Eq. 33

Ecorr

qi q j erf ( β | ri − rj |) keβ N 2
1
= − ke ∑
−
∑q
2 (i, j )∈M
| ri − rj |
π i=1 i
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Here, erf() is the error function, erfc() is the complementary error function, β is the Ewald coefficient, and

Yrec(ri) is the reciprocal potential at position of ri. which is calculated by using helPME library177. The first
term on the right-hand side of eq. 20 is the correction for intramolecular interactions when i and j are within
1-4 interactions in molecule M.

LJ energy calculation
In the GIST-2016, the LJ energy of the unit cell is estimated by:
Eq. 34
N

N'

A(i, j )

i

j

| rj − ri |*12

Elj ! ∑ ∑

−

B(i, j )
| rj − ri |*6

As with the electrostatic energy (eq. 34), the asterisk here denotes that the distance between two atoms
are calculated by the minimum image convention; therefore, interactions longer than half the length of the
unit cell’s diagonal are not included in the LJ energy in GIST-2016.

In PME-GIST, the total LJ energy is broken down into short-range and long-range correction terms (eq. 35).
The short-range term accounts for the LJ interactions within a defined distance cutoff and the long-range
correction term is an estimation of the LJ interactions beyond this cutoff.
Eq. 35

Elj = Elj _ short + Elj _ corr
Eq. 36
N

N'

Elj _ short = ∑ ∑
i

j

A(i, j )
| rj − ri |

12

−

B(i, j )
| rj − ri |6

Eq. 37

2
Elj _ corr = − π N ρ Brcut −3
3
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Eq. 38

B=

N N
2
∑∑ B
N (N −1) i j>i (i, j)

In which, r is the number density of all species in the system and 𝐵" is the weighted average B parameter
of all particle interaction pairs in the system.

GIST calculates the ensemble energy density of each voxel in the unit cell. To do this, for every frame, the
energies of each atom are calculated and assigned to the corresponding voxels where the atoms occupy
(for water molecules, all the energy is assigned to the voxel in which the oxygen atom resides). Averaging
the voxel energies over all frames of the trajectory gives the estimate of the reported voxel energy. The
energy densities of each voxel are the voxel energies divided by the voxel volume. In GIST-2016, the
assignment of every particle’s energy to each voxel is straightforward given both the electrostatic (eq. 29)
and LJ energy (eq. 34) are pairwise decomposable and the energy terms involve two atoms are evenly split
then assigned to the two corresponding voxels. In PME-GIST, the energy terms involving two atoms (eq.
31 and the first term on the right-hand side of eq. 33) are evenly divided between the two atoms and then
assigned to the voxels that those atoms occupy. The terms that have only one atom index (the reciprocal
term and second term on right-hand side of eq. 33) are simply assigned to voxel where the atom resides.

Comparison of energies calculated by GIST-2016, PME-GIST, and Amber-PMEMD
Figure 24 shows a comparison between energy densities computed using PME-GIST and GIST-2016 for
a neat system of 922 water molecules at a temperature of 300K and 1 bar of pressure. The average and
standard deviation of the voxel energy densities calculated by PME-GIST and GIST-2016 are -0.2824 ±
0.0811 and -0.2822 ± 0.0810 kcal/molÅ3. The relative differences in the energy densities for the neat system
computed by PME-GIST and GIST-2016 are within 2% of each other for the majority of voxels (98%) and
the average unsigned relative difference is 0.54%. We also compare the GIST-2016 and PME-GIST
calculated voxel water energies in these solute-water systems, for the 32 solute-water systems we study
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here, the average unsigned relative difference in voxel water energy calculated by GIST-2016 and PMEGIST is 0.45%.

While these values are relatively small on a per voxel basis, when the energies are summed over all voxels
to compute the total energy for the system, the difference is significant (6.5 kcal/mol). Importantly, PMEGIST system energies are consistent with Amber-PMEMD with a total difference of 0.019 kcal/mol
(0.0002%) for the system of 922 water molecules (Table 6).

Figure 24. Voxel energy density calculated by GIST-2016 and PME-GIST for neat water.
Left: Voxel energy densities calculated by GIST-2016 and PME-GIST. Each blue dot represents one of the
249,242 voxels in the system. Right: The relative differences in voxel energy densities calculated by GIST2016 and PME-GIST. The relative difference was obtained by taking the difference between the voxel
energy densities calculated by PME-GIST and GIST and dividing by the GIST-calculated voxel energy.

Table 6. Ensemble energy of pure water system calculated by different methods
Ensemble energy

Difference to Amber-PMEMD

GIST-2016

-8791.425 (0.243)

6.519

PME-GIST

-8797.925 (0.198)

0.019

Amber-PMEMD

-8797.944 (0.198)

0
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The system comprises 922 water molecules. The GIST calculations analyzed the results of a 100 ns
trajectory (50,000 frames) generated by the production phase of a neat water MD simulation. The standard
errors are indicated in parentheses.

Speed of PME-GIST
In GIST-2016, the potential energy of atom i is computed by looping over the electrostatic and LJ
interactions between atom i and all other atoms j in the system. This is a time consuming N2 loop which
resulted in the energy calculations taking approximately 90% of the total GIST computation time. In contrast,
the computational complexity of the PME energy calculations in PME-GIST is NlogN. This significantly
speeds up the GIST energy computation time. Here, we tested the speed of PME-GIST on a solvated
monomer and dimer of SARS Cov-2 main protease (PDB ID: 6W63178). The energy calculation in PMEGIST was sped up 27- to 65-fold depending on the system size （Table 7）.

Table 7. Computation times per frame of PME-GIST and GIST-2016
System

# Residuesa

# Atom b

GIST-2016c

GPU-GIST d

PME-GISTc

6W63_monomer

306

50951

40.15 s

0.33 s

1.47 s (´27)

6W63_dimer

612

83566

146.25 s

1.10 s

2.23 s (´65)

a. Number of protein residues.
b. Total number of atoms in the system, which consists of protein and water molecules.
c. GIST-2016 and PME-GIST were performed on a single Intel i7-5820 core, the number in the bracket
shows the speedup of PME-GIST to GIST-2016.
d. GPU-GIST146 was performed on Nvidia GTX1080Ti (all cores).
Energy calculations were conducted on 100 frames, and the times shown are the average times per frame.
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Small molecule solvation free energies calculated by TI
Solvation free energies are typically computed by alchemical free energy methods, which require
simulations over a series of nonphysical intermediate states169. In contract, IST can yield estimates of both
the solvation energy and entropy and differences in end-states from a single simulation of each end-state.
Although many studies have applied IST and GIST for solvation free energy calculations, long-range
interactions have not been included in these works, and high order entropies have been either
approximated or neglected completely145–147. Here, in order to investigate how the inclusion of long-range
interactions affect GIST’s accuracy in calculating solvation energy(DEsolv), we computed solvation energies
using GIST-2016 and PME-GIST and then compared them to the solvation energies obtained by TI.

We first used TI to calculate the free energy, entropy, and energy of solvation of 32 small molecules. The
molecules were chosen to cover a wide range of solvation free energies referenced by the FreeSolv
database. As shown in Figure 25, the solvation free energies we obtained from TI were consistent with the
values reported in the FreeSolv database (R2 = 0.95) and correlated comparably as well as FreeSolv to the
experimental values (R2 = 0.90). For the entire set of molecules, the average standard errors in solvation
free energy, TDS and energy are 0.06 kcal/mol, 0.65 kcal/mol and 0.65 kcal/mol. The full set of TI calculated
solvation free energies, entropies, and energies for all 32 compounds can be found in Table S7.
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Figure 25. The solvation free energy of 32 molecules calculated by TI.
Left: correlation of solvation free energies calculated by TI vs. values in FreeSolv; Right: correlation of
solvation free energies calculated by TI vs. experimental values. Each dot represents the data for a
molecule. The solid lines represent linear regression fits to the data for which the equations are shown. The
experimental error bars were collected from the FreeSolv database, while the computational error bars are
the standard errors from multiple simulations.

To assess the accuracy of solvation energy (DEsolv) calculated by PME-GIST and GIST, we compared the
solvation energies to that obtained by TI. As shown in Figure 26, PME-GIST gave solvation energy values
closer to those of TI than GIST did. The average difference between solvation energies calculated by GIST2016 and TI is -3.8 ± 0.7

kcal/mol (unsigned average difference: 3.8 ± 0.7 Kcal/mol), in contrast, the

average difference decreases to 0.1 ± 0.7 kcal/mol (unsigned average difference: 0.8 ± 0.7 kcal/mol) in
PME-GIST vs TI. the DH values calculated by GIST are almost always more negative than those of TI,
suggesting that GIST has a systematic error in its solvation energy calculation. The systematic error
observed in GIST-2016 arises from the minimal image convention algorithm for calculating pairwise
energies. This algorithm imposes a system size dependence on the energy calculation, as longer-range
interactions are calculated as the system size increase. In PME-GIST, this system size dependence is
removed by implementation of the PME-based energy calculation. Interestingly, the solvation energies
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calculated in GIST-2016 and PME-GIST are both highly correlated to those calculated by TI. (Figure 27).
The solvation energies for 32 molecules calculated by GIST and PME-GIST can be found in Table S8.

Figure 26. Solvation energy calculated by GIST-2016, PME-GIST compared to TI.
The names of the 32 molecules are displayed on the x-axis. Bars represent mean values, and error bars
represent standard errors in the differences between the GIST calculations and TI. Both PME-GIST and
GIST-2016 were performed on the entire system for each solute.
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Figure 27. Correlation of solvation energy calculated by PME-GIST, GIST-2016 with TI.
The average standard error of DEsolv calculated by PME-GIST and GIST-2016 is 0.18 kcal/mol and 0.19
kcal/mol, respectively. The black dashed diagonal line corresponds to perfect agreement between the GIST
and TI. Solvation energies calculated by PME-GIST and GIST-2016 are shown in blue and orange,
respectively. Each dot represents data for a molecule. The solid lines represent the linear regression fit for
each data set with equations shown on the graph. The error bars reflect the standard error of the
calculations.

GIST end states solvation entropy calculations
The non-ideal part of IST138 entropy for an infinitely dilute solvated rigid solute can be written as (eq. 39):
Eq. 39

S = Ssw + Ssww + O(3) + ...
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In which:
Eq. 40

Ssw = −

kB ρ 0
g (r,ω ) ln g sw (r,ω )drdw
Ω ∫ sw

and
Eq. 41

1 ρ0
Ssww = − k B 2 ∫ g sw (r,ω )g sw ( r ′,ω ′ ){g sww (r,r ',ω ,ω ′ ) ln g sww (r,r ',ω ,ω ′ )}drdr ′dω dω ′
2 Ω
Where kB is Boltzmann’s constant, r0 is number density of bulk water, W is the total volume of the
orientational space (for asymmetric molecules such as water molecules, W = 8p2, ); r and w are the position
and orientation variables of the water molecule, respectively.
funtion and

gsww (r,r ',ω ,ω ′ )

gsw (r,ω ) is

the solute-water correlation

is the solute-water-water correlation. Due to both computational expense and

difficulities with sparse sampling in calculating the 2nd order ( Ssww) and high order entropy terms, only the
1st order entropy term which accounts for the soute-water correlation entropy is calculated in GIST (eq. 40).
In this study, we break down the solvation entropy into two terms (eq. 42):
Eq. 42

ΔSsolv = ΔSsw + ΔO(2)
where, DSsw is the solute-water entropy change of two states and solute-water entropy equals to 0 in the
initial state. DO(2) is difference of 2nd and higher order entropy terms between the final state and initial state.
The solute-water entropy values for 32 small molecules can be found in Table S9. Subtracting the solutewater entropy calculated by GIST from the solvation entropy calculated by TI gives a direct estimate of the
solvation entropy contributed by high order entropy terms (thus DO(2)).

The correlation between GIST calculated entropies and those computed from TI are shown in Figure 28.
While the curves are highly correlated (R2 = 0.92), the slope, 0.60, is significantly different than 1. A simple
approximation for the higher order terms (DO(2) = -0.4 DSsw) changes the slope to be close to 1. With this
simple correction for DO(2), as shown in Figure 29, the solvation free energies calculated by PME-GIST
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are highly consistent with those calculated by TI (R2 = 0.99, mean unsigned difference = 0.4 kcal/mol) and
with experimental results (R2 = 0.88 and mean unsigned difference = 1.4 kcal/mol) (Figure 30). While the
simple scaling factor (-0.4) we report here works well in this study of small molecules, for macromolecules
such as proteins with more complex surface topographies, the relationship between solute-water entropy
and higher order entropy terms deserves further investigation.

Figure 28. The correlation between solute-water entropy and solvation entropy.
Each dot represents a molecule, and the solid line is the linear regression line whose equation is written on
the graph. The average standard errors of TDSsw and TDS are 0.13 kcal/mol and 0.65 kcal/mol, respectively.
Error bars reflect the standard errors of the calculations.
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Figure 29. Solvation free energies calculated by PME-GIST, with or without entropy correction.
The mean standard errors of solvation free energy calculated by PME-GIST and TI are 0.26 kcal/mol and
0.06 kcal/mol, respectively. The mean unsigned difference in solvation free energies calculated by PMEGIST and TI are 0.4 kcal/mol (with DO(2) correction) and 6.2 kcal/mol (without DO(2) correction). Each dot
represents the data of a molecule, and the solid lines represent the linear regression lines whose equations
are written on the graph. The area shaded grey represents values within ± 1 kcal/mol of the regression
lines. Error bars reflect the standard errors of the calculations.
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Figure 30. Solvation free energy calculated with PME-GIST compared to experimental data.
Each dot represents the data of a molecule, and the solid line is the linear regression line whose equation
is written on the graph. The area shaded grey represents values within ± 1 kcal/mol of the regression lines.
The error bars reflect the standard error of the calculations or the uncertainties of the experimental values
collected from the FreeSolv database.

The perturbation of water molecules upon solvation of small molecules
In contrast to TI and FEP methods, which calculate the free energy change for the entire system, PMEGIST provides information on the spatial distribution of the free energy contributions to the molecular
solvation. It is often convenient to investigate the thermodynamics of a region such as the binding site of a
protein. Here, to investigate whether the total solvation free energy can be well estimated by considering
only the voxels proximal to the solute, we estimate the contribution by integrating the energies and entropies
over only voxels that are within various distances of the heavy atoms of each of the solutes. This is
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illustrated for the benzene-water system as a representative example (Figure 31 and Figure 32). As shown
in Figure 31, the largest perturbation of surrounding water molecules occurs within 5 Å of the solvated
benzene molecule, while the calculated solvation energies and entropies flatten after the region is extended
to approximately 10 Å from the solute179. A similar pattern is observed for all solutes (see Supporting
Materials) which is consistent with similar observations in a study using the a density-functional approach180.
We can also estimate the free energy of solvation by integrating only over voxels that are within a certain
distance of the solute heavy atoms instead of over the entire system. When the integration region extends
to include all voxels within 10 Å of the solute heavy atoms, the correlation between the local PME-GIST
free energies and TI calculated free energies has an R2 of 0.99 for all 32 molecules with a slope of 0.98 and
a mean unsigned error of 0.37 (Table S10).

Figure 31. Perturbation of water molecules in adjacent region.
The solvation energies, entropies, and free energies were calculated by integrating the voxels within an
increasing radius (1 Å – 15 Å) from the heavy atoms of benzene. The initial value (about -8 kcal/mol) reflects
the energy change on benzene upon solvation; both curves are initially flat because there are no water
molecules within ~3 Å of the benzene molecule.

91

Figure 32. A GIST energy and entropy map around a benzene molecule.
The benzene molecule is represented by the CPK model at the center. Regions where the water entropies
are very unfavorable (entropy density is lower than -0.007 kcal/mol/Å3) are colored in red. Regions where
the water energies are very favorable (energy density is lower than -0.39 kcal/mol/Å3) are colored in blue.

The decomposition of solvation free energy
GIST calculates energy and entropy terms separately in a single simulation; this can provide additional
insight into the solvation process. For solvation energy, given that PME-GIST decomposes the system
energy to the level of each atom, the respective energy changes of solute atoms and water molecules can
also be examined. Interestingly, as shown in Figure 33, favorable interactions between the solutes and
water molecules constitutes the main contribution to the solvation energies of the 32 small molecules. We
also observe compensation between energy and entropy for each molecule (Figure 34).
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Figure 33. The decomposition of solvation energy change.
The molecules are ranked from hydrophobic to hydrophilic by the experimental free solvation energy. Bars
represent mean values, and the error bars correspond to standard errors.
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Figure 34. The energy-entropy compensation in solvation of small molecules.
Each dot represents the data for a molecule, and the solid line is the linear regression fit to this data whose
equation is written on the graph. The solvation energy and entropy values are calculated by PME-GIST
with the DO(2) correction added.

3.3.6 Discussion of Higher Order Entropy Scaling
The negative correlation between DSsw and DO(2) suggests that the entropy change from the first order
entropy term is offset to a significant degree by an opposing change in the higher order entropy terms. A
negative correlation between first order entropy and high order entropy terms was reported in other
studies147,181, but its physical significance was not discussed. We consider that this observation is largely
due to two behaviors of water molecules. First, the more strongly a water molecule is held rigid by the field
of the solute, the less sensitive its position and orientation are to the fluctuations of neighboring water
molecules. At one limit, in neat water there is no solute and the IST entropy of a water molecule is -14.05
cal/(mol·K)182, which, in IST, is entirely accounted for in the 2nd and higher order IST terms, as the 1st order
IST term is zero. In the other limit, a water molecule is held entirely rigid by the solute and is insensitive
the fluctuations of neighboring water molecules. In this limit, all of the IST entropy would be accounted for
in the 1st order terms and the higher order terms would be zero. In this case, a rigid water molecule would
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have the entropy of that in an ideal crystal water which, in IST, is -30.75 cal/(mol·K)183. A simple linear fit
between these two limits yields a negative correlation between the 1st order term and the 2nd and higher
order terms with a slope of -0.46 (Figure 35), which is close to -0.40 we report in this study.

Figure 35. The entropy of a water molecule in the crystal and liquid states.
S1 denotes the 1st order entropy term, and S2+ denotes the 2nd and higher order entropy terms. The “S2+
+14.05” is equivalent to DO(2) and S1 is equivalent to DSsw in eq. 40.

The second behavior comes from the fact that water molecules are most correlated with their water
neighbors in the 1st shell. A study by Lazaridis et al. showed that 90% of neat water entropy comes from
the correlations between neighbors in the 1st shell184. If a water molecule has no neighbors, then the high
order IST terms can be approximated as zero, whereas if a fluid has the bulk number of neighbors then the
2nd and higher order entropy terms make the full contribution. Here, we also propose that the 2nd and higher
order entropy terms of a water molecule would linearly scale by the number of its water neighbors in the
first solvation shell. The average number of water neighbors for water molecules within 5 Å of the solutes
is about 90% the water neighbor number of a bulk water molecule (Table S11). When the contributions of
the 2nd and higher order entropy terms are scaled by this value, the slope of the negative correlation is
estimated to be -0.41, which is quite close to the value estimated in this study (-0.4). Again, our study of
small molecules only covers a limited 1st order entropy range. Whether this negative linear correlation
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between the 1st order entropy term and high order entropy terms can be applied broadly, such as to water
molecules on the more complex surfaces of macromolecules, requires further investigation.

3.3.7 Conclusions
In this study, we developed the methodology and implemented PME-based electrostatic treatment and
long-range LJ corrections into GIST. This increased the accuracy of GIST energetic calculations to fully
agree with those of modern MD engines. With its precise energy calculations, we applied PME-GIST end
states analyses to measure the solvation energies of small molecules and obtained results highly consistent
with the alchemical TI method without the need to simulate many intermediate states. We also examined
quantitatively the entropy contributions from higher order terms that are truncated in GIST, by comparing
the solute-water entropy from GIST with the solvation entropy from TI calculations. Using a simple
correction for higher order entropy ((DO(2) = -0.4 DSsw) together with the enhanced accuracy in the energy
calculation the PME-GIST end-states calculations can yield solvation free energies in agreement with those
calculated by the TI method to within 0.2 kcal/mol. Furthermore, we also investigated the perturbation of
water molecules upon solvation by varying the GIST integration region surrounding the solutes. The
convergence of solvation energy and entropy at approximately 10 Å from the solutes suggests that the
perturbation to water molecules extends to about three shells and the water molecules beyond this distance
make negligible contributions to the solvation free energy. Our results also support the local approximations
that are often used in displaced solvent functionals185–187. The utility of PME-GIST end-state method in
calculating solvation free energies as demonstrated here could potentially extend the application of IST to
free energy calculations of more complex scenarios such as drug-target binding. The code for PME-GIST
is available on the CPPTRAJ GitHub (https://github.com/Amber-MD/cpptraj).
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3.3.8 Supporting information
Table S6. The solvation free energies of 32 small molecules calculated by Thermodynamic Integration. The
calculations were conducted at three different temperatures with three replicates (a, b, c). In this study, the
entropies were calculated by the finite-difference method. The standard errors of the mean (SEM) are
reported for solvation free energies (DG), temperature multiplied by solvation entropies (TDS), and
enthalpies (DH) at 300 K for each molecule.

270K_a 270K_b 270K_c 300K_a 300K_b 300K_c 330K_a 330K_b 330K_c
acetamide

-9.15

-9.04

-9.21

-8.52

-8.67

-8.58

-8.27

-8.23

-8.08

acetone

-3.69

-3.85

-3.85

-3.19

-3.34

-3.32

-2.74

-2.58

-2.72

alachlor

-12.55

-12.19 -12.30 -10.04

-9.85

-9.99

-9.17

-9.01

-9.23

aldicarb

-9.00

-8.92

-9.13

-8.19

-7.81

-8.11

-7.10

-7.06

-7.19

aniline

-6.56

-6.85

-6.64

-5.80

-5.91

-5.80

-5.26

-5.23

-5.29

-11.32 -11.06

-9.71

-9.85

-9.80

-9.53

-9.60

-9.51

-1.12

-0.94

-1.00

-0.65

-0.55

-0.52

benzamide

-10.86

benzene

-1.74

bromacil

-16.17

-15.92 -16.38 -14.57

-14.64 -14.26 -13.30 -13.30 -13.26

caffeine

-18.69

-18.94 -18.92 -17.01

-16.77 -16.97 -15.57 -15.76 -15.67

captan

-9.66

-9.38

-9.58

-8.32

-8.17

-8.15

-7.37

-7.48

-7.32

0.38

0.35

0.34

0.95

1.06

1.09

1.51

1.51

1.67

endrin

-5.05

-4.90

-5.08

-3.73

-3.96

-3.87

-2.92

-3.11

-3.33

ethane

1.85

1.84

1.97

2.30

2.22

2.31

2.51

2.54

2.57

-11.07 -10.82

-9.91

-9.96

-9.95

cyclohexene

-2.00

-1.66

fenuron

-12.35

heptanal

-3.33

-3.33

-3.49

-2.46

-2.41

-2.39

-1.88

-1.89

-1.82

hydrazine

-7.61

-7.33

-7.53

-7.82

-7.83

-7.15

-6.04

-6.33

-5.93

imidazole

-8.32

-8.36

-8.27

-7.73

-7.68

-7.63

-7.22

-6.98

-7.26

isobutane

1.73

1.84

1.74

2.31

2.49

2.31

2.70

2.80

2.79

ketoprofen

-13.25

-12.24 -12.34 -11.24

-13.26 -13.37 -11.66

-11.58 -11.22 -10.64 -10.52 -10.30

methane

1.88

2.01

1.91

2.20

2.25

2.26

2.49

2.39

2.43

methanol

-3.20

-3.35

-3.36

-2.86

-2.96

-2.92

-2.56

-2.79

-2.63

morpholine

-6.20

-6.12

-6.21

-5.71

-5.53

-5.66

-4.82

-4.78

-4.71

naproxen

-12.22

pebulate

-6.28

-6.04

-6.01

-4.41

-4.53

-4.36

-3.22

-3.41

-3.29

phenol

-5.80

-5.75

-5.82

-5.19

-5.09

-5.37

-4.52

-4.64

-4.66

pirimor

-14.39

propane

1.83

-12.27 -12.18 -11.10

-15.02 -14.57 -13.24
1.86

1.85

2.30
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-11.01 -10.89 -10.03 -10.30 -10.01

-13.18 -13.35 -11.27 -11.39 -11.29
2.33

2.33

2.50

2.68

2.61

pyrene

-7.78

-7.79

-7.72

-6.70

-6.80

-6.81

-5.86

-5.75

-5.82

pyrrole

-5.23

-5.12

-5.12

-4.49

-4.51

-4.49

-4.03

-3.89

-4.03

quinone

-7.01

-6.99

-6.77

-6.22

-6.29

-6.16

-5.42

-5.52

-5.71

simazine

-12.16

-12.87 -12.61 -11.32

-11.63 -11.51

-9.91

-9.76

-9.89

terbacil

-15.98

-15.82 -16.02 -13.85

-14.10 -14.35 -12.69 -13.05 -12.96

Table S7. The end state energy of each solute. Solute intramolecular energies were calculated by
CPPTRAJ. The calculations were conducted on three MD replicates (MD1, MD2, MD3) for each solute.
Solute
intramolecular
energy

System
energy by
PME-GIST

System
Water
energy by number in
GIST-2016 system

acetamide_MD1

12.29

-13615.61

-13633.09

1428.00

acetamide_MD2

12.56

-13615.30

-13633.41

1428.00

acetamide_MD3

12.66

-13615.67

-13633.80

1428.00

acetone_MD1

3.39

-13446.65

-13446.33

1409.00

acetone_MD2

3.47

-13446.15

-13445.94

1409.00

acetone_MD3

3.48

-13446.10

-13445.94

1409.00

alachlor_MD1

6.94

-19133.58

-19140.30

2004.00

alachlor_MD2

7.36

-19133.65

-19141.25

2004.00

alachlor_MD3

5.88

-19136.42

-19141.04

2004.00

aldicarb_MD1

-52.92

-17271.92

-17158.81

1797.00

aldicarb_MD2

-53.26

-17272.11

-17158.46

1797.00

aldicarb_MD3

-53.26

-17272.48

-17158.92

1797.00

aniline_MD1

13.17

-14118.72

-14137.76

1481.00

aniline_MD2

12.77

-14118.98

-14137.71

1481.00

aniline_MD3

12.87

-14119.27

-14138.05

1481.00

benzamide_MD1

-14.17

-14302.81

-14267.37

1494.00

benzamide_MD2

-14.25

-14302.65

-14267.00

1494.00

benzamide_MD3

-14.25

-14303.34

-14267.68

1494.00

benzene_MD1

2.37

-14286.59

-14284.44

1497.00

benzene_MD2

2.38

-14285.99

-14283.77

1497.00

benzene_MD3

2.37

-14286.50

-14284.16

1497.00

bromacil_MD1

112.66

-17293.91

-17512.20

1833.00

bromacil_MD2

112.34

-17294.12

-17511.75

1833.00
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bromacil_MD3

113.28

-17292.15

-17511.77

1833.00

caffeine_MD1

65.40

-15186.98

-15310.84

1602.00

caffeine_MD2

64.13

-15188.84

-15309.82

1602.00

caffeine_MD3

64.76

-15187.48

-15310.11

1602.00

captan_MD1

-12.69

-16992.07

-16959.68

1776.00

captan_MD2

-12.89

-16992.82

-16960.00

1776.00

captan_MD3

-13.23

-16993.11

-16959.36

1776.00

cyclohexene_MD1

1.45

-14849.02

-14845.04

1556.00

cyclohexene_MD2

1.47

-14848.74

-14845.00

1556.00

cyclohexene_MD3

1.46

-14849.03

-14844.99

1556.00

endrin_MD1

-3.85

-17876.08

-17861.47

1871.00

endrin_MD2

-4.16

-17876.95

-17861.38

1871.00

endrin_MD3

-4.31

-17876.50

-17860.95

1871.00

ethane_MD1

0.00

-12167.51

-12160.35

1275.00

ethane_MD2

0.00

-12167.23

-12160.42

1275.00

ethane_MD3

0.00

-12167.60

-12160.87

1275.00

fenuron_MD1

18.60

-15472.15

-15502.04

1623.00

fenuron_MD2

18.74

-15472.26

-15502.51

1623.00

fenuron_MD3

18.84

-15471.62

-15502.02

1623.00

heptanal_MD1

-2.71

-15025.16

-15012.63

1573.00

heptanal_MD2

-2.71

-15025.88

-15013.37

1573.00

heptanal_MD3

-2.63

-15026.08

-15013.33

1573.00

hydrazine_MD1

-0.01

-11377.16

-11370.02

1191.00

hydrazine_MD2

-0.01

-11378.39

-11371.32

1191.00

hydrazine_MD3

-0.01

-11378.05

-11370.92

1191.00

imidazole_MD1

2.01

-13520.91

-13518.15

1416.00

imidazole_MD2

2.00

-13521.11

-13517.92

1416.00

imidazole_MD3

2.01

-13520.94

-13517.91

1416.00

isobutane_MD1

2.71

-14471.43

-14470.16

1517.00

isobutane_MD2

2.75

-14471.84

-14470.60

1517.00

isobutane_MD3

2.78

-14472.03

-14470.61

1517.00

ketoprofen_MD1

-23.44

-18298.64

-18244.74

1910.00

ketoprofen_MD2

-22.97

-18297.33

-18244.23

1910.00

ketoprofen_MD3

-23.17

-18297.58

-18243.82

1910.00

methane_MD1

0.00

-11584.21

-11577.56

1214.00

methane_MD2

0.00

-11584.36

-11577.41

1214.00

methane_MD3

0.00

-11584.37

-11577.45

1214.00
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methanol_MD1

0.00

-12106.69

-12099.73

1268.00

methanol_MD2

0.00

-12106.55

-12099.85

1268.00

methanol_MD3

0.00

-12106.07

-12099.47

1268.00

morpholine_MD1

-0.13

-14060.20

-14053.10

1472.00

morpholine_MD2

-0.15

-14059.84

-14052.57

1472.00

morpholine_MD3

-0.08

-14060.01

-14052.80

1472.00

naproxen_MD1

-1.60

-18223.69

-18213.41

1907.00

naproxen_MD2

-1.14

-18223.12

-18213.52

1907.00

naproxen_MD3

-0.92

-18223.03

-18213.99

1907.00

pebulate_MD1

-13.89

-18165.34

-18130.36

1899.00

pebulate_MD2

-14.26

-18166.53

-18130.91

1899.00

pebulate_MD3

-14.56

-18166.48

-18129.99

1899.00

phenol_MD1

9.17

-14268.06

-14279.15

1496.00

phenol_MD2

9.16

-14268.24

-14279.77

1496.00

phenol_MD3

8.97

-14268.58

-14279.61

1496.00

pirimor_MD1

144.72

-17534.67

-17816.88

1865.00

pirimor_MD2

143.90

-17537.30

-17817.72

1865.00

pirimor_MD3

145.04

-17533.95

-17816.90

1865.00

propane_MD1

0.90

-13072.22

-13067.32

1370.00

propane_MD2

0.88

-13072.85

-13067.68

1370.00

propane_MD3

0.87

-13072.38

-13067.36

1370.00

pyrene_MD1

-2.75

-15966.78

-15953.89

1671.00

pyrene_MD2

-2.92

-15967.27

-15954.30

1671.00

pyrene_MD3

-2.97

-15968.11

-15955.28

1671.00

pyrrole_MD1

12.67

-13296.25

-13314.60

1395.00

pyrrole_MD2

12.63

-13296.04

-13314.22

1395.00

pyrrole_MD3

12.65

-13296.20

-13314.23

1395.00

quinone_MD1

-52.79

-14288.74

-14176.03

1485.00

quinone_MD2

-52.73

-14288.55

-14176.17

1485.00

quinone_MD3

-53.16

-14289.25

-14175.78

1485.00

simazine_MD1

253.54

-16435.97

-16935.87

1773.00

simazine_MD2

254.05

-16434.53

-16935.34

1773.00

simazine_MD3

254.74

-16433.09

-16935.35

1773.00

terbacil_MD1

156.30

-16165.84

-16470.99

1724.00

terbacil_MD2

155.15

-16168.34

-16471.50

1724.00

terbacil_MD3

154.24

-16170.53

-16472.20

1724.00
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Table S8. Solute-water entropy calculated by GIST. The calculations were conducted on three MD
replicates.
Solute-water entropy
acetamide_MD1

-9.69

acetamide_MD2

-10.10

acetamide_MD3

-9.62

acetone_MD1

-8.63

acetone_MD2

-8.30

acetone_MD3

-8.72

alachlor_MD1

-25.53

alachlor_MD2

-25.43

alachlor_MD3

-25.24

aldicarb_MD1

-18.72

aldicarb_MD2

-18.50

aldicarb_MD3

-18.47

aniline_MD1

-12.66

aniline_MD2

-12.01

aniline_MD3

-12.16

benzamide_MD1

-13.97

benzamide_MD2

-13.80

benzamide_MD3

-14.14

benzene_MD1

-9.87

benzene_MD2

-9.98

benzene_MD3

-9.60

bromacil_MD1

-23.23

bromacil_MD2

-23.08

bromacil_MD3

-22.72

caffeine_MD1

-21.58

caffeine_MD2

-21.70

caffeine_MD3

-22.10
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captan_MD1

-19.35

captan_MD2

-19.94

captan_MD3

-19.41

cyclohexene_MD1

-9.07

cyclohexene_MD2

-9.58

cyclohexene_MD3

-9.06

endrin_MD1

-17.99

endrin_MD2

-18.02

endrin_MD3

-17.99

ethane_MD1

-5.38

ethane_MD2

-5.30

ethane_MD3

-5.09

fenuron_MD1

-19.21

fenuron_MD2

-19.07

fenuron_MD3

-18.85

heptanal_MD1

-13.74

heptanal_MD2

-13.93

heptanal_MD3

-13.50

hydrazine_MD1

-8.78

hydrazine_MD2

-9.21

hydrazine_MD3

-9.69

imidazole_MD1

-9.63

imidazole_MD2

-9.34

imidazole_MD3

-9.52

isobutane_MD1

-7.38

isobutane_MD2

-7.51

isobutane_MD3

-7.52

ketoprofen_MD1

-26.02

ketoprofen_MD2

-25.68

ketoprofen_MD3

-26.06

methane_MD1

-4.08

methane_MD2

-3.82

methane_MD3

-3.69

methanol_MD1

-6.85

methanol_MD2

-6.94

methanol_MD3

-7.01

morpholine_MD1

-12.84

morpholine_MD2

-12.53

morpholine_MD3

-13.05
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naproxen_MD1

-22.69

naproxen_MD2

-22.98

naproxen_MD3

-23.39

pebulate_MD1

-20.86

pebulate_MD2

-20.42

pebulate_MD3

-20.88

phenol_MD1

-12.05

phenol_MD2

-12.24

phenol_MD3

-12.17

pirimor_MD1

-26.06

pirimor_MD2

-26.06

pirimor_MD3

-25.67

propane_MD1

-6.59

propane_MD2

-6.24

propane_MD3

-6.29

pyrene_MD1

-16.14

pyrene_MD2

-16.95

pyrene_MD3

-16.74

pyrrole_MD1

-9.88

pyrrole_MD2

-10.44

pyrrole_MD3

-10.11

quinone_MD1

-10.75

quinone_MD2

-10.95

quinone_MD3

-10.73

simazine_MD1

-24.08

simazine_MD2

-23.52

simazine_MD3

-23.93

terbacil_MD1

-22.15

terbacil_MD2

-22.41

terbacil_MD3

-22.30
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Table S9. Correlations between local approximations of PME-GIST free energies and TI free energy
calculations at different integrating distances. Here, the radius is the integrating distance around the
solute heavy atoms. The slope and R-squared value of the linear regression curve of the locally integrated
solvation free energies with solvation free energies calculated by TI for 32 molecules are reported. mean
unsigned differences (kcal/mol) are reported for solvation free energies calculated by PME-GIST
(integrating regions of increasing radius around the solute heavy atoms) and those calculated by TI
(accounting for the entire system).

Table S10.
Radius (Å)
Average first
shell waterSlope
neighbor R-squared
number forMean unsigned
Difference
water molecules
in regions
within certain
distances to the
solute heavy
atoms. The
energy, entropy,
and free energy
perturbation upon
solvation of the
remaining 31
molecules are
shown in the
supplementary
information.
Region within
certain distance
to the solute
3
3.5

3

4

5

6

7

8

9

10

0.82 0.81 0.98 0.98 0.96 0.98 0.98 0.98
0.73 0.97 0.99 0.99 0.99 0.99 0.99 0.99
2.34 1.58 0.37 0.66 0.43 0.46 0.33 0.37

4

4.5

5

5.5

6

6.5

7

7.5

8

8.5

9

9.5

10

acetamide

4.33

4.47 4.62 4.76 4.87 4.97 5.05 5.10 5.13 5.15 5.16 5.18 5.19 5.20

5.21

acetone

4.28

4.42 4.56 4.69 4.80 4.91 5.00 5.07 5.11 5.13 5.15 5.16 5.18 5.19

5.20

alachlor

4.19

4.35 4.48 4.61 4.73 4.85 4.94 5.02 5.06 5.09 5.11 5.13 5.15 5.16

5.17

aldicarb

4.16

4.33 4.49 4.63 4.75 4.87 4.96 5.03 5.08 5.10 5.12 5.14 5.16 5.17

5.18

aniline

4.26

4.42 4.57 4.70 4.82 4.93 5.02 5.08 5.11 5.14 5.15 5.17 5.18 5.19

5.20

benzamide

4.28

4.43 4.58 4.71 4.83 4.93 5.02 5.07 5.11 5.13 5.15 5.16 5.18 5.19

5.20
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benzene

4.28

4.41 4.54 4.66 4.78 4.88 4.98 5.05 5.09 5.12 5.14 5.15 5.17 5.18

5.19

bromacil

4.23

4.38 4.53 4.66 4.78 4.88 4.98 5.04 5.09 5.11 5.13 5.15 5.16 5.18

5.19

caffeine

4.18

4.36 4.53 4.68 4.81 4.92 5.01 5.07 5.10 5.12 5.14 5.16 5.17 5.19

5.19

captan

4.21

4.35 4.50 4.63 4.76 4.87 4.97 5.04 5.08 5.10 5.12 5.14 5.16 5.17

5.18

cyclohexene

4.31

4.43 4.53 4.65 4.76 4.86 4.96 5.04 5.09 5.12 5.14 5.15 5.17 5.18

5.19

endrin

4.22

4.36 4.50 4.62 4.75 4.86 4.96 5.03 5.07 5.10 5.12 5.14 5.16 5.17

5.18

ethane

4.47

4.54 4.62 4.71 4.80 4.90 4.99 5.07 5.11 5.14 5.15 5.17 5.18 5.19

5.20

fenuron

4.18

4.35 4.50 4.64 4.76 4.88 4.98 5.04 5.08 5.11 5.13 5.14 5.16 5.18

5.19

heptanal

4.25

4.39 4.52 4.64 4.76 4.86 4.96 5.03 5.08 5.11 5.13 5.15 5.16 5.18

5.19

hydrazine

4.48

4.62 4.75 4.86 4.96 5.04 5.10 5.14 5.16 5.18 5.19 5.20 5.21 5.22

5.22

imidazole

4.28

4.44 4.60 4.73 4.85 4.95 5.04 5.10 5.13 5.15 5.16 5.18 5.19 5.20

5.21

isobutane

4.43

4.48 4.57 4.67 4.77 4.87 4.97 5.05 5.09 5.12 5.14 5.16 5.17 5.19

5.20

ketoprofen

4.12

4.31 4.47 4.62 4.75 4.86 4.95 5.02 5.06 5.09 5.11 5.13 5.15 5.16

5.18

methane

4.52

4.58 4.66 4.75 4.84 4.93 5.01 5.08 5.13 5.15 5.16 5.18 5.19 5.20

5.21

methanol

4.36

4.52 4.66 4.77 4.88 4.97 5.04 5.10 5.13 5.15 5.17 5.18 5.19 5.20

5.21

morpholine

4.20

4.40 4.56 4.69 4.81 4.92 5.01 5.07 5.11 5.13 5.15 5.16 5.18 5.19

5.20

naproxen

4.18

4.33 4.49 4.63 4.76 4.87 4.97 5.03 5.07 5.10 5.12 5.14 5.15 5.17

5.18

pebulate

4.20

4.35 4.49 4.61 4.73 4.84 4.94 5.02 5.06 5.09 5.11 5.13 5.15 5.17

5.18

phenol

4.28

4.43 4.56 4.69 4.80 4.91 4.99 5.06 5.10 5.12 5.14 5.16 5.17 5.18

5.20

pirimor

4.12

4.30 4.46 4.60 4.73 4.85 4.95 5.02 5.07 5.09 5.11 5.13 5.15 5.17

5.18

propane

4.46

4.51 4.59 4.68 4.78 4.88 4.98 5.05 5.10 5.13 5.14 5.16 5.18 5.19

5.20

pyrene

4.11

4.29 4.45 4.59 4.72 4.84 4.95 5.02 5.07 5.09 5.11 5.13 5.15 5.17

5.18

pyrrole

4.31

4.45 4.59 4.72 4.83 4.93 5.02 5.08 5.12 5.14 5.16 5.17 5.18 5.20

5.20

quinone

4.27

4.42 4.57 4.71 4.83 4.93 5.02 5.08 5.11 5.13 5.15 5.16 5.18 5.19

5.20

simazine

4.18

4.36 4.52 4.65 4.78 4.89 4.98 5.05 5.09 5.11 5.13 5.15 5.16 5.18

5.19

terbacil

4.25

4.40 4.54 4.67 4.79 4.89 4.99 5.05 5.09 5.11 5.13 5.15 5.16 5.18

5.19
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FUTURE DIRECTIONS
Machine learning-based approaches for virtual screening have gained much attention recently. In this thesis,
we showed that biases in widely used database have prevented the machine learning models from learning
the physical principles that govern molecular recognition. In order to leverage the power of machine learning
for drug discovery application, such as virtual screening or binding affinity prediction, effort should be
directed to construct large, diverse, and high-quality protein-ligand binding databases. Machine learning
models and algorithms have existed since the 1980s; however, it is not until 2010s when large, high-quality
image and voice recording datasets became available that machine learning achieved remarkable
successes in these fields. We believe that in the drug discovery field, machine learning approaches have
vast protential, but similarly large, high-quality datasets are essential for machine such approaches to
achieve breakthroughs.

As for the future of PME-GIST, in this thesis, we obtained an empirical estimator for high order entropy and
found that it works well for small molecule solvation; however, its applicability to more complex systems
such as host-guest binding or protein-ligand binding deserves further investigation. Only when energy is
calculated precisely and entropy is estimated appropriately, GIST can be used as a robust tool to
understand the thermodynamic forces for molecular recognition.
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